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Abstract 
Postoperative delirium (POD) is a major complication following surgery and is 
considered the most common complication among older adults following cardiac surgery; 
with up to 87% of patients being affected (Whitlock, Vannucci, & Avidan, 2011). 
Dexmedetomidine, a highly selective α2 agonist, inhibits the release of norepinephrine 
presynaptically causing analgesia and inhibits central nervous system stimulation in the 
postsynaptic neurons causing decreased blood pressure and heart rate; together, 
contributing to the effects of analgesia, anesthesia, and sedation (Naaz & Ozair, 2014). 
The purpose of this systematic review was to analyze the current literature and examine 
the effects of dexmedetomidine on POD in the adult cardiac surgical population. A 
comprehensive literature review was completed using CINAHL, PubMed, and Medline 
focusing on the pathology of postoperative delirium, the physiology of cardiac surgery, 
and the pharmacodynamics of dexmedetomidine. Guidelines set forth by PRISMA and 
Inouye and Charpentier’s multifactorial model were utilized to assist in the identification 
of eligible studies. Study analysis was completed by creating study specific and data 
outcome tables. Critical appraisal of individual RCTs was performed utilizing the Critical 
Appraisal Skills Programme (CASP) checklist.  A cross study analysis table was also 
created comparing the results of all eligible studies against one another. The findings of 
this systematic review determined that in the adult cardiac surgical population, 
dexmedetomidine was associated with a decreased incidence of POD; however, the 
results for time to extubation, ICU LOS (length of stay), and hospital LOS varied amid 
the studies examined.    
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Dexmedetomidine and Postoperative Delirium in the Adult Cardiac Surgical Population: 
A Systematic Review 
Background/Statement of the Problem 
 Delirium is categorized as a neurological/behavioral condition initiated by a 
temporary disturbance of normal neuronal functioning resulting from systemic 
dysfunction (Maldonado et al., 2009). Postoperative delirium (POD) is an extremely 
common and unfortunate occurrence following surgery, particularly cardiac surgery, 
additionally, it is considered to be the most common surgical complication in older 
adults. The incidence of POD in the vascular and cardiac surgical population is high (up 
to 87% of patients); furthermore, the risk of mortality increases 10%-20% for every 48 
hours that the surgical patient remains in a delirious state (Whitlock et al., 2011).   
Postoperative delirium is an often-unavoidable neurobehavioral disturbance, and 
places both patients and providers in a precarious situation. Healthcare providers must 
treat these disturbances as they arise to prevent potential harm to the patient; however, 
these treatments repeatedly place the cardiac surgical patient at increased risk for 
developing further complications following an already complex course of recovery. 
Often, medications administered to treat the delirious behavior have a sedative effect, 
thus leading to decreased depth and frequency of respiratory effort, as the somnolent 
patient is now susceptible to the development of atelectasis, and the potential for 
acquiring pneumonia. Postoperative delirium remains a major and often unforeseen 
complication following cardiac surgery. This unexpected obstacle can hinder the 
recovery of cardiac surgical patients, thus increasing the incidence of morbidity and 
mortality amongst this fragile and vulnerable group. Dexmedetomidine, a highly selective 
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alpha-2 (α2) agonist inhibits the release of norepinephrine presynaptically causing 
analgesia and inhibits central nervous system stimulation in the postsynaptic neurons 
causing decreased blood pressure and heart rate; together, contributing to the effects of 
analgesia, anesthesia, and sedation (Ji et al., 2013). Dexmedetomidine provides numerous 
desirable benefits and effects, including anxiolysis, analgesia, and sympatholysis, 
producing a decline in the release of systemic norepinephrine subsequently enhancing 
hemodynamic stability and positively influencing myocardial O2 supply and demand, all 
leading to and potentiating the added benefits of myocardial protection (Ji et al., 2013). 
Dexmedetomidine has also been shown to provide moderate anti-inflammatory effects, in 
addition to added protective benefits for the organs of the vessel-rich group consisting of 
the heart, lungs, brain, and kidneys (Ji et al., 2013).  
The purpose of this study was to investigate whether dexmedetomidine, an α2 
receptor agonist, decreases the occurrence of POD in cardiac surgical patients. During the 
postoperative period, pharmacological agents including propofol, midazolam, and 
morphine are frequently utilized as adjunctive therapy for pain management, anxiolysis, 
and/or sedation. A systematic review was conducted in order to further explore the topic 
and disseminate the literature to offer insight and direction regarding this significant and 
potentially life-altering hindrance.  
Next, the review of the literature will be presented.      
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Literature Review 
A comprehensive review of the literature was performed utilizing CINAHL 
(Cumulative Index to Nursing and Allied Health Literature) as well as 
MEDLINE/PubMed. An advanced search approach was implemented utilizing keywords 
“cardiac surgery” AND “dexmedetomidine” AND “delirium.” Restrictions applied to the 
search were English language, peer reviewed, and human subjects. A ten-year time 
period was utilized for the search (2007-present).     
Postoperative Delirium 
 Postoperative delirium is an acute psychological disorder characterized as 
restlessness, agitation, combativeness, hallucinations, irritability, and confusion. 
Additionally, it has been linked to an increase in morbidity and mortality, increased 
healthcare costs, increased risk of hospital-acquired infections, prolonged ICU and 
subsequent hospital stay, and significant cognitive and functional decline, often requiring 
an intermediate or long-term facility placement (Maldonado, et al., 2009). Shehabi et al. 
(2009) recommended that cardiac surgical patients already considered at increased risk 
for the development of POD be carefully treated for post-surgical pain management; as 
opioids have the probability of potentiating the dysfunctional cognitive effects of POD. 
Moreover, it is believed that there is a correlation between inadequate postoperative pain 
control and the risk for the development of POD following surgery though no direct 
statistical information has been published. Approximately 57% of cardiac surgery 
patients have been diagnosed with POD annually (Park et al., 2014). It is postulated that a 
number of risk factors increase an individual’s probability of developing POD following 
cardiac surgery. Risk factors include: atrial fibrillation, preexisting cognitive disorder, 
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perioperative medications, history of delirium, and other metabolic disturbances, however 
the direct cause of POD has yet to be identified (Park et al., 2014). Additional 
contributors to POD include hematocrit < 30%, decreased cardiac output, use of an intra-
aortic balloon pump, use of inotropic medications, prolonged intubation > 24 hours, 
postoperative dysrhythmias, infusion of > 4 units of PRBCs or > 1 unit of FFP, CO2 
levels > 45 mmHg, hyper/hypoglycemia, hyperthermia, and elevated levels of urea 
(Jannati, Bagheri-Nesami, Sohrabi, Yazdani-Cherati, & Mazdarani, 2014). Park et al. 
(2014) reported that the added stress of major surgery, in particular cardiac surgery, 
significantly increased the occurrence of POD. This was due to the complexity of the 
cardiac surgical procedure and pharmacologic ingredients, including anesthetic 
substances administered throughout the perioperative phase, coupled with complications 
endured during the postoperative period.  
 Brown et al. (2016) hypothesized a correlation between POD following cardiac 
surgical procedures and an increase in postoperative resource use and management. In 
order to examine the potential association between POD and increased postoperative 
resource use, Brown et al. (2016) conducted a randomized control trial to examine the 
effects of POD on increased length of stay in the ICU. A total of 66 participants were 
included in the study. The study results demonstrated a 56% occurrence of POD (37 out 
of 66 patients), with 26 patients (39.4%) diagnosed on post-op day 1, 8 patients (12.1%) 
diagnosed on post-op day 2, and the remaining 3 delirious patients (4.6%) diagnosed on 
post-op day 3 (Brown et al., 2016).  
 Brown et al. (2016) also determined a correlation between increased length of 
stay in the intensive care unit (LOS-ICU) and delirium, revealing that LOS-ICU was 
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higher in patients that exhibited delirium (75.6 hours for delirious patients compared to 
29.7 hours for patients whom did not exhibit delirium; 𝑝𝑝 = 0.002). Additionally, overall 
hospital LOS was increased in patients that exhibited delirium (9 days versus 7 days for 
patients whom remained cognitively intact; 𝑝𝑝 = 0.006). 
 Leslie, Marcantonio, Zhang, Leo-Summers, and Inouye (2008) conducted a study 
to determine the overall one-year healthcare costs related to delirium. A total of 841 
participants were included in the controlled trial. Of the 841 participants, 109 individuals 
exhibited delirious behavior. The109 patients that were deemed delirious were then 
monitored for a 12-month time frame. The total cost of healthcare resources required to 
treat those individuals was calculated and compared against the cost of healthcare 
resources required by the remaining 732 patients that did not exhibit delirium. Leslie et 
al., (2008) determined that the overall cost of healthcare expenses was approximately 
40% higher annually for delirious patients ($69,498 per patient compared to $47,958 
annually for each of the remaining participants unaffected by delirium; 𝑝𝑝 < 0.001). In 
addition to increased healthcare costs, Leslie et al. (2008) determined that the overall 
financial impact of delirium was extensive and exceeded the total healthcare costs of both 
diabetes mellitus and falls. Likewise, they reported that the findings of their study 
highlighted the necessity for increased efforts to abate this substantial and costly illness 
(Leslie et al., 2008).  
CAM-ICU. Delirium in cardiac surgical patients is measured utilizing the 
Confusion Assessment Method for the ICU (CAM-ICU), (Ely & Vanderbuilt University, 
2002). CAM-ICU is a modified version and adapted from the Confusion Assessment 
Method (CAM). The CAM-ICU is a brief and convenient method to determine adequate 
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cerebral perfusion by assessing a patient’s mental status. The CAM-ICU is the 
measurement tool utilized for this specific patient population due in part to the high level 
of patient acuity coupled with the potential for surgical and procedural complications 
during the postoperative period. During the immediate postoperative period, cardiac 
surgical patients are admitted into the intensive care unit following their surgical 
procedure. It is then that the registered nurse begins the first of many CAM-ICU 
measurements. These measurements are carefully documented as they serve as a 
reference point for each consecutive assessment.  
 CAM-ICU measures four neurological characteristics (Figure 1). The first feature 
measured with the CAM-ICU includes an acute alteration or variation in mental status 
from the standard functioning. The second feature is characterized as lack of 
concentration, followed by an altered level of alertness. and lastly, disorganized thoughts. 
In order to characterize the patient as being delirious, both characteristics 1 and 2 must be 
positive, as well as either characteristic 3 or 4 must also exist (Brummel et al., 2013). The 
CAM-ICU delirium assessment tools provide an easy-to-follow, sequential guide that 
allows for the early detection and subsequent mediation of potentially harmful cognitive 
and neurological effects (Brummel et al., 2013).  Additionally, the CAM-ICU is the most 
widely accepted delirium assessment tool utilized by medical experts and is due in part to 
its ease of use, brevity of measurement, consistency, and validity (Park et al., 2014).  
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RASS Scoring System. Prior to completing the CAM-ICU, a separate 
measurement tool must first be utilized. The Richmond Agitation Sedation Scale (RASS) 
is a required component necessary for accurate measurement and calculation of the 
CAM-ICU (Nickson, 2015). The RASS measures depth of sedation and assists as an easy 
and reliable indicator of level of consciousness (Figure 2). A RASS score must be 
Figure 1. CAM-ICU Assessment Tool 
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obtained prior to performing the CAM-ICU. Once a RASS score is obtained, this number 
is then utilized to assist in the early detection of POD. 
 
 
Guenther et al. (2010) examined the validity and reliability of the confusion 
assessment method and its ease of use within the intensive care unit. Guenther, et al. 
(2010), examined the CAM-ICU assessment scores of 54 ICU patients. The CAM-ICU 
assessments were performed on all participants with the scores then reviewed and 
confirmed by a psychiatrist and two ICU physicians. Following the accurate diagnosis of 
delirium utilizing the CAM-ICU flowsheet, it was concluded that the assessment tool had 
a sensitivity of 88% (95% confidence interval, 69%-98%) and 92% (74%-99%), as well 
as specificities of 100% (85%-100%), high-level inter-rater reliability (kappa, 0.96; 0.87-
1.00), and required 50 seconds (interquartile range, 40-120 seconds) in delirious patients 
Figure 2. RASS Scoring Scale (Nickson, 2015). 
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vs 45 seconds (interquartile range, 40-75 seconds) for those participants without delirium 
in order to conclude the assessments (Guenther, et al., 2010). Following these findings, 
Guenther, et al., (2010) concluded that in addition to its sensitivity, specificity, and inter-
rater reliability, the CAM-ICU flowsheet is a brief, valid, and reliable bedside delirium 
assessment instrument. Furthermore, the flowsheet was shown to have infrequent false-
negatives, while those that did occur were likely to reflect the fluctuating course along 
the delirium spectrum.   
Cardiac Surgery Procedures 
The incidence of POD in vascular and cardiac surgical populations is high (up to 
87% of patients) and the risk of mortality increases 10%-20% for every 48 hours that the 
surgical patient remains in a delirious state (Whitlock et al., 2011). According to Ji et al. 
(2013), in the United States, coronary artery disease (CAD) remains the leading cause of 
morbidity and mortality, with a 30-day mortality rate of approximately 1.2% for 
individuals who have undergone on-pump coronary artery bypass graft (CABG).  
Coronary Artery Bypass Graft (CABG). CABG is performed to reestablish 
adequate blood flow through a coronary vessel that has been significantly narrowed from 
plaque that has built up over years along the coronary vessel wall occluding blood flow 
and ultimately the delivery of oxygen to vital organs, primarily the heart. During this 
procedure, a vessel(s) is harvested from the patient’s leg(s) and is reimplanted within the 
coronary vasculature, bypassing the occluded vessel. During this invasive surgical 
procedure, the patient requires the use of cardiopulmonary bypass to induce cardioplegia. 
Cardioplegia allows for the temporary cessation of cardiac activity while continuing to 
perfuse the vital organs with oxygen-rich blood. The induction of cardioplegia provides 
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the cardiothoracic surgeon optimal surgical conditions for successful completion of this 
intricate procedure. 
 Valve Replacement. Valve replacement procedures are performed to correct a 
defective or faulty cardiac valve. The malfunctioning valve occurs secondary to coronary 
disease, as a consequence of an untreated virus occurring throughout the lifespan, or as a 
result of a congenital disorder. Typically, the mitral and aortic valves are the most 
commonly replaced. The diseased valve can be stenosed in which the flow of blood is 
impeded, and this often leads to hypertrophy of the preluding chamber. The replaced 
valve can either be tissue or mechanical with each offering both advantages and 
disadvantages to either selection. Additionally, valve replacement surgery can be 
performed utilizing a transapical approach, penetrating the apex of the heart, 
transfemorally, guiding the replacement of the valve through the femoral artery, or 
through a thoracotomy, cutting through the sternum to allow direct access to the heart.  
 As previously mentioned, the noxious insult of cardiac surgery in and of itself 
significantly increases the risk of developing POD. According to Ji et al. (2013), major 
complications following cardiac surgery include POD, acute renal failure (ARF), 
infection, stroke, perioperative myocardial infarction, coma, heart block, cardiac 
dysrhythmias, and cardiac arrest. Therefore, the use of dexmedetomidine and survival 
rates following cardiac surgery have been examined in the literature. Ji et al. (2013) 
examined the survival rates of cardiac surgical patients during in-hospital stay, at thirty 
days, and at the one-year mark. A correlation between the intraoperative administration 
of dexmedetomidine and increased postoperative survival rates were noted. Ji et al. 
(2013) also noted that following cardiac surgery, the non-dexmedetomidine group 
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demonstrated an increased morbidity and long-term mortality rate. In the study, it was 
noted that patients who received dexmedetomidine intraoperatively demonstrated 
increased survival rates during the in-hospital phase and at the one-year mark, however, 
no difference was noted in either group at the 30-day mark (Ji et al., 2013). According to 
Ji et al., (2013) the in-hospital mortality rate for the DEX group was 1.5% versus 4.0% in 
the non-DEX group (0.357; 95% CI, 0.128 to 0.993; 𝑝𝑝 = 0.0398), whereas the one-year 
mortality rate for the DEX group was 3.2% versus 6.9% in the non-DEX group (0.447; 
95% CI, 0.218 to 0.919; 𝑝𝑝 = 0.0251). It was also noted that the intraoperative 
administration of dexmedetomidine during cardiac surgery decreased circulating 
catecholamines, particularly norepinephrine (NE) concentrations, decreased cardiac 
contractility and heart rate and decreased overall consumption of myocardial oxygen 
therefore, ultimately leading to an increase in blood flow to the myocardium (Ji et al., 
2013).  
Dexmedetomidine 
Dexmedetomidine has been found to promote a more natural and physiological 
sleep cycle without substantial respiratory depression and is associated with reduced 
opioid requirement (Maldonado et al., 2009). Dexmedetomidine has no effect on 
acetylcholine, the neurotransmitter located within the neuromuscular junction involved in 
muscle contraction, therefore it does not contain anticholinergic properties. Furthermore, 
Dexmedetomidine contains no GABAergic (gamma aminobutyric acid) effects unlike 
Propofol, that has a direct effect on the GABA neurotransmitter, which is responsible for 
the inhibition of nerve transmission in the brain (Maldonado et al., 2009).      
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 Dexmedetomidine is a highly-selective α2 receptor agonist that contains 
substantial desirable benefits and effects, including anxiolysis, analgesia, sympatholytic, 
decline in the release of systemic norepinephrine. Thus, significantly enhancing 
hemodynamic stability, and therefore positively influencing myocardial O2 supply and 
demand, thus potentiating the added benefits of myocardial protection (Ji et al., 2013).  
Dexmedetomidine is typically used for sedation following cardiac surgery as a 
bridge to wean patients from mechanical ventilation, however, it also contains the added 
benefit of anxiolysis following extubation at low-dose infusions. It is also postulated that 
dexmedetomidine provides anti-delirium capabilities while inflicting minimal respiratory 
depression and providing significant analgesia (Park et al., 2014). In addition to its 
sedative properties, dexmedetomidine has also been shown to provide moderate anti-
inflammatory effects, as well as a protective benefit for the organs of the vessel-rich 
group consisting of the heart, lungs, brain, and kidneys (Ji et al., 2013).  
Quite often adjuvant pharmacological therapy is utilized in the cardiac surgical 
population with the intention of treating postoperative pain, anxiety, and delirious 
behavior. In addition to dexmedetomidine, medications utilized as adjuvant therapy 
during the perioperative phase include the sedative-hypnotic, propofol; the opioid, 
morphine; and the benzodiazepine; midazolam or lorazepam.   
Adjuvant therapy 
 Nelson, Muzyk, Bucklin, Burdney, and Gagliardi (2015) explored the use of 
dexmedetomidine in the prevention of delirium in critically ill ICU patients. In order to 
examine its effectiveness in decreasing postoperative delirium, Nelson et al. (2015) 
limited their search to RCTs, controlled trials, and comparative studies. The primary 
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outcome examined was to assess the effectiveness of dexmedetomidine in the prevention 
of POD. Additionally, Nelson et al. (2015) theorized that ICU patients sedated with 
dexmedetomidine would exhibit significantly less episodes of delirium as compared to 
ICU patients receiving non-dexmedetomidine sedation. By evaluating delirium 
assessment scores obtained from the Confusion Assessment Method for the ICU (CAM-
ICU) and Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) in 
conjunction with the Delirium Rating Scale (DRS) combined with the use of 
dexmedetomidine versus the use of a comparative sedative delirium scores and clinical 
outcomes were analyzed. Nelson et al. (2015) performed an electronic search in 
MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews utilizing key 
search terms including “dexmedetomidine,” “delirium,” and “ICU psychosis.” Study 
subjects included adults, 18 years of age and older with an ICU hospital admission. A 
total of 71 studies were initially identified, with 42 of those meeting inclusion criteria, 
however, an additional 39 were excluded as they were identified as being case reports, 
nonrandomized trials, or review articles. Ultimately three were evaluated and their 
findings summarized (Nelson et al., 2015).  
 In the first RCT examined by Nelson et al. (2015), Pandharipande et al. (2008) 
performed a randomized, double-blinded study examining ICU patients who were 
intubated and mechanically ventilated for 24 hours. The patients included in this study 
were hospitalized for a variety of ailments including sepsis and acute respiratory distress 
syndrome (ARDS). Individuals with baseline dementia, hemorrhagic stroke, ischemic 
stroke, and intracranial injury were excluded from the study (Pandharipande et al., 2008). 
This study consisted of 103 participants ages 45 and older. Study participants were 
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treated with an infusion of the highly selective α2 agonist dexmedetomidine, or the 
benzodiazepine, lorazepam and the occurrence of delirium was evaluated. Participants 
were followed closely for 12 days and assessed for signs and symptoms of confusion, 
hallucinations, and restlessness by utilizing the CAM-ICU assessment tool. This study 
concluded that the patients who received dexmedetomidine as their sedative 
demonstrated more coma-free days and less delirium, than those treated with lorazepam 
(7 days dexmedetomidine versus 3 days lorazepam, 𝑝𝑝 = 0.01). Additionally, it was noted 
that these patients had significantly greater time spent within one point of their RASS 
goal (67% dexmedetomidine versus 55% lorazepam, 𝑝𝑝 = 0.008) (Pandharipande et al., 
2008). However, although Pandharipande et al. (2008) determined a decrease in the 
occurrence of delirium, they did note a significant safety issue regarding the occurrence 
of bradycardia in select patients with the use of dexmedetomidine (Nelson et al., 2015). 
In a second RCT study examined by Nelson et al. (2015) authors Shehabi et al. 
(2008) performed a randomized, double-blinded study and looked at the rates of POD in 
cardiac surgical patients. The patients included in this study were adults 60 years of age 
and older who underwent on-pump cardiac surgery. The study consisted of 299 
participants; 152 participants were treated with an infusion of the highly selective α2 
agonist dexmedetomidine, versus 147 participants that were treated with the opioid, 
morphine, and the occurrence of postoperative delirium was then evaluated. Participants 
were followed closely for the first five days following cardiac surgery and were assessed 
for delirium utilizing the CAM-ICU assessment tool. Shehabi et al. (2008) concluded that 
there was no significant difference in the occurrence of postoperative delirium in patients 
that were sedated with dexmedetomidine versus morphine (8.5% in dexmedetomidine 
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versus 15% in morphine, 𝑝𝑝 = 0.088). However, it is important to note that a severe 
limitation was noted. The open label use of morphine was used for breakthrough pain in 
both groups, thus potentially tainting the final outcome of the study.  Lastly, Shehabi et 
al. (2008) also determined a significant safety issue regarding the occurrence of 
bradycardia in select patients with the use of dexmedetomidine (Nelson et al., 2015). 
In the third and final study examined by Nelson et al. (2015) authors Maldonado 
et al. (2009) compared the incidence of POD in cardiac surgery patients by performing an 
RCT comparing the varying effects of the highly selective α2 agonist dexmedetomidine, 
the sedative-hypnotic, propofol, and the benzodiazepine, midazolam. Participants 
included were between the ages of 18-89 undergoing elective valve surgery. Patients 
were followed closely for the first three days following cardiac surgery and delirium 
indicators were evaluated by implementing the DSM-IV-TR criteria in conjugation with 
the DRS. Maldonado et al. (2009) concluded that the patients who received 
dexmedetomidine as their sedative demonstrated less delirium than those treated with 
either propofol or midazolam (10% dexmedetomidine, 44% propofol, and 44% 
midazolam in intention-to-treat analysis, 𝑝𝑝 < 0.001). Additionally, they determined that 
those individuals treated with dexmedetomidine who exhibited delirious behaviors were 
in fact noted to have fewer days of delirium than either the propofol or midazolam groups 
(2 patient days dexmedetomidine, 45 patient days propofol, and 75 patient days 
midazolam, 𝑝𝑝 < 0.001) (Maldonado et al., 2009). A significant limitation was noted 
however; as all groups were allotted the use of “as-needed” benzodiazepines, therefore, 
potentially impacting the significance of the study results.   
Next, the theoretical framework will be presented.   
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Theoretical Framework 
The utilization of a theoretical framework in research serves as an organized 
outline pertaining to a particular theory and provides insight into the research topic of 
choice. The use of a theoretical framework or conceptual model strengthens the research 
and supports the reasoning behind why a particular topic requires further study or 
investigation. Following extensive research, Inouye and Charpentier’s (1996) 
multifactorial model was the preferred theoretical framework selected to guide this 
research plan.     
 The Multifactorial Model created by Sharon K. Inouye, MD, MPH and Peter A. 
Charpentier, MPH was the conceptual framework chosen to address the research topic: 
does the administration of dexmedetomidine decrease the incidence of POD in adult 
cardiac surgery patients? Inouye and Charpentier’s Multifactorial Model explains the 
complex relationship between delirium; baseline vulnerability factors, or predisposing 
factors; and precipitating factors, or noxious insults (Inouye & Charpentier, 1996, p. 852) 
(Figure 3). During their research phase, Inouye and Charpentier discovered a 
multifaceted association between the vulnerability that patients experience at baseline 
(during admission) and those that they experience during hospitalization, known as 
precipitating factors or insults (Inouye & Charpentier, 1996, p. 852).   
 Inouye and Charpentier’s model describes four axes that are believed to be 
precipitating factors for delirium. Axis 1 defines the use of urinary catheters, physical 
restraints, and being bed-bound as immobility, whereas Axis 2 describes the use of 
narcotics, anticonvulsants, antiemetics, and tranquilizers as medications (Inouye & 
Charpentier, 1996, p. 855). Axis 3 explains any iatrogenic event as a hospital-acquired 
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pressure ulcer (HAPU), hemorrhage, urinary tract infection, fluid overload, transfusion 
reaction, or IV catheter complications, and lastly, Axis 4 is defined as intercurrent illness, 
which includes infection, respiratory compromise, dehydration, or malnutrition (Inouye 
& Charpentier, 1996, p. 855). Following a prospective study based on their four axes as 
described above, Inouye and Charpenter (1996) were able to identify five independent 
precipitating factors for delirium; those five factors consist of malnutrition, the use of 
physical restraints, the use of a urinary catheter, greater than three medications added, 
and any iatrogenic event (p. 855). The Multifactorial Model lends itself to a variety of 
specialty fields interested in the study of factors influencing delirium. One such research 
study utilized this conceptual framework and adapted it toward postoperative delirium in 
the cardiovascular intensive care unit.   
Figure 3. Inouye & Charpentier’s Multifactoral Model 
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Chang, Tsai, Lin, Chen, and Liu (2008) utilized a modified version of Inouye & 
Charpentier’s multifactorial model. In this retrospective chart review, the multifactorial 
framework for POD in patients following cardiac surgery was described as three phases 
which include: predisposing factors (preoperative variable), aggravating factors 
(intraoperative variable), and precipitating factors (postoperative variable). Chang et al., 
(2008) defined predisposing factors as those that cannot be modified such as body mass 
index (BMI), ethnicity, age, gender, smoking history, psychiatric history, alcoholism, and 
past medical history (p. 569). Aggravating factors were explained as: type of surgery 
performed, time on cardiopulmonary bypass, circulatory arrest time, ischemic time, 
anesthesia, intraoperative hypothermia and blood transfusions. Additionally, precipitating 
factors include any of the following: LVEF < 30%, postoperative cardiogenic shock, 
hemorrhage > 1 L, RBC transfusion > 1 L, acute infection (SIRS), HCT < 30%, SaO2 < 
90%, or PaCO2 < 25 or > 45 mm Hg (Chang et al., 2008, p. 569). By utilizing Inouye & 
Charpentier’s multifactorial model, Chang et al., (2008) were able to successfully 
implement a conceptual framework and adapt it toward POD in adult cardiac surgical 
patients. 
 The utilization of this conceptual model can be easily adapted toward the research 
topic questioning the administration of dexmedetomidine and its effects on the incidence 
of POD in adult cardiac surgical patients. Utilizing the outline presented by Mateo and 
Foreman (2013), internal factors that should be addressed when reviewing a theory 
include: clarity, consistency, adequacy, logical development, and level of theory 
development. In addition, factors that should be addressed regarding external criticism 
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include reality convergence, utility, significance, discrimination, scope, and complexity 
(p. 124). 
The main concepts of Inouye and Charpentier’s Multifactorial Model are clear 
and easily understood. Key concepts such as the four axes that constitute the conceptual 
model, as well as the five predisposing independent variables are described sufficiently 
and are kept consistent throughout their framework. The Multifactorial Model, although 
adequate to a degree because it explains and covers each of its axes in detail, does require 
further investigation as to whether early detection of delirium successfully prevents the 
onset or duration for hospitalized patients. This model has been logically developed, as 
statements described in the framework are well supported and have been utilized in 
extensive research. The Multifactorial framework has been utilized and adopted for 
nearly twenty years and has been frequently applied to numerous medical settings by 
researchers. Such settings include palliative care, geriatrics, and cardiac surgery. 
 The Multifactorial Model applies to nursing with the assumption that predisposing 
factors affect the incidence of delirium in hospitalized patients. The theory does display a 
utilitarian quality, as it assists the researcher with explaining a phenomenon, as well as 
generating a hypothesis. However, the theory lends itself to the concept of delirium, 
therefore it is limited regarding its field of study. Delirium affects a vast number of 
hospitalized patients; therefore, the utilization of a detailed framework is crucial in the 
early identification of risk factors affecting patients, thus preventing complications 
leading to increased length of hospital stay. The Multifactorial Model designed by Inouye 
and Charpentier does generate a theory that is not sufficiently addressed by other models. 
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The scope of this theory provides interactive statements that are testable. Additionally, 
this model is easily applicable to practice within a variety of settings. Lastly, the  
Multifactorial Model lacks complexity. It is a theory that is easily understood and 
congruent in regard to its concepts.   
 Inouye and Charpentier designed a fundamental practice theory that has been 
adapted toward numerous studies encircling the predisposing factors of delirium. 
Utilizing the five independent predisposing factors for delirium in addition to the four 
axes described in the multifactorial model, the effects of dexmedetomidine on the 
incidence of POD in adult cardiac surgical patients can be further. 
 In addition to Inouye and Charpentier’s Multifactorial Model, Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) framework was also utilized 
(Moher et al., 2009). PRISMA is an evidenced-based framework that consists of a 27-
item checklist (Figure 4) to be used when reporting on or generating a systematic review 
(PRISMA, 2015). In addition to the PRISMA checklist, the use of a PRISMA flowchart 
(Figure 5) was implemented. The PRISMA flow diagram consists of four main sections 
including identification, screening, eligibility, and included studies (Moher, Liberarti, 
Tetzlaff, Altman, & The PRISMA group, 2009). Utilizing Inouye and Charpentier’s 
Multifactoral Model in conjunction with the PRISMA framework; a systematic review 
examining the effects of dexmedetomidine on POD in cardiac surgery patients was 
conducted.   
Next, the methods will be presented.      
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 Figure 4. PRISMA Checklist  
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Figure 5. PRISMA Flow Diagram 
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Method 
Purpose 
The purpose of this study was to examine if the administration of 
dexmedetomidine decreased the incidence of POD in adult cardiac surgical patients. 
According to Mateo and Forman (2014), a study design is the arrangement of research 
that specifies observations and interventions; and ensures neutrality (p. 135). In order to 
further investigate this clinical question, a systematic review of multiple RCTs was the 
method of choice selected. Human subjects did not participate in this evaluation; 
therefore, International Review Board (IRB) approval was not required for guiding this 
systematic review.   
Inclusion/Exclusion Criteria 
Inclusion criteria for the studies included: (a) adults 18 years of age and older, (b) 
patients undergoing cardiac surgery, (c) the utilization of dexmedetomidine for sedation 
(d) the use of a comparison sedative(s) for experimental studies, and (e) the use of a 
delirium assessment tool such as the CAM-ICU or the DSM-IV-TR (Diagnostic and 
Statistical Manual of Mental Disorders-4th Ed.-Text Review), (Spitzer, Gibbon, Skodol, 
Williams, & First, 2002). 
Exclusion criteria for the studies included: (a) pediatric patients, those under the 
age of 18, (b) surgical patients other than cardiac, (c) dexmedetomidine not utilized as a 
sedative, and (d) studies that did not include a specific delirium assessment tool (CAM, 
CAM-ICU, or DSM-IV-TR) 
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Search Strategy 
A detailed search strategy was performed utilizing CINAHL (Cumulative Index to 
Nursing and Allied Health Literature) as well as MEDLINE/PubMed. An advanced 
search approach was implemented using keywords “cardiac surgery” AND 
“dexmedetomidine” AND “delirium.” Restrictions applied to the search were English 
language and human subjects.   
Data Collection 
Data collected from individual studies included: study purpose, design, and 
location; total number of participants, cardiac surgical procedure(s) performed, 
postoperative sedative protocol initiated including medication and administration dosage. 
Additionally, the number of patients included in each study group and specific delirium 
assessment tool implemented were also identified.  
Critical Appraisal 
 Critical appraisal of literature was performed utilizing CASP (Critical Appraisal 
Skills Programme). CASP (Table 1) provides an easy to use 3-step approach for evidence 
appraisal and offers eight critical appraisal tools to utilize when synthesizing research 
(Critical Appraisal Skills Programme [CASP], 2017). This invaluable tool assists 
researchers in determining a study’s strengths, outcomes, and usefulness. Following 
individual study summary and analysis a complete cross study analysis was implemented.   
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A. Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue?    
2. Was the assignment of patients to treatments 
randomized? 
   
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
   
4. Were patients, health workers, and study personnel 
“blind” to treatment? 
   
5. Were the groups similar at the start of the trial?    
6. Aside from the experimental intervention, were the 
groups treated equally? 
   
B. What are the results? 
7. How large was the treatment effect?  
8. How precise was the estimate of the treatment 
effect? 
 
C. Will the results help locally? YES  CAN’T 
TELL  
NO 
9. Can the results be applied in your context?    
10. Were all clinically important outcomes 
considered? 
   
11. Are the benefits worth the harms and costs?    
 
 
Table 1. Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist  
Note. CASP checklist completed on all studies that meet inclusion criteria.  
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Data Synthesis & Cross Study Analysis 
Data synthesis and cross study analysis were completed immediately following 
critical appraisal of individual studies. The cross-study analysis compared postoperative 
sedative protocols initiated, including medications administered along with dosage, 
overall incidence of delirium, total length of delirium, time to extubation, ICU LOS 
(length of stay), and overall hospital LOS. 
Next, the results will be presented.      
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Results 
PRISMA 2009 Flow Diagram 
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Figure 6. Completed PRISMA flow diagram demonstrating article identification, screening, 
eligibility, and inclusion (Moher et al., 2009).  
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The completed flow diagram as depicted in Figure 6 provides a visual 
interpretation demonstrating how the final six studies chosen to implement this 
systematic review were selected. An initial search utilizing the search term “delirium” 
resulted 14,702 studies among the selected databases. The addition of search term 
“postoperative” narrowed the resulted studies to 2,047. Next, the search term “cardiac 
surgery” was added and further narrowed the result to 544 studies. Lastly, 
“dexmedetomidine” was included in the search terms and a final total of 31 articles 
resulted. Prior to article screening, 7 articles were excluded as duplicates leaving a total 
of 24 articles to be screened. Following article screening, 18 studies were excluded for 
not meeting inclusion criteria as previously identified. Finally, the remaining 6 studies 
were evaluated and selected to complete this systematic review to determine whether the 
use of dexmedetomidine in the adult cardiac surgical population decreases the incidence 
of postoperative delirium.  
 Each of the six studies identified and reviewed for this systematic review include 
an explanation of the results with pertinent study findings identified. Study specific data 
tables are outlined in Appendix A (Tables A1-A6). Key information obtained for the data 
tables include: study purpose, design, location, sample size, method, and cardiac surgical 
procedure(s) performed. Next, outcome data collection tables were created with results 
summarized in Appendix B (Tables B1-B6). Study specific findings identified include: 
the incidence of delirium, mean length of delirium, time to extubation, ICU LOS (length 
of stay), and hospital LOS. Critical appraisal data tables of individual studies followed 
(Appendix C, Tables C1-C6) to assist in assessing the validity, reliability, and 
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applicability of studies through a series of 11 questions. Lastly, a cross-study analysis 
data table was created (Appendix D) comparing the results of each study. 
Individual Studies  
 The single-center, randomized, prospective study by Park et al. (2014) (Appendix 
A, Table A-1) evaluated the postoperative sedative effects of dexmedetomidine 
associated with a lower incidence of delirium, compared with the postoperative sedative 
protocol of remifentanil in patients undergoing open-heart surgery with cardiopulmonary 
bypass (CPB). A total of 142 patients who underwent cardiac surgery were divided into 
two groups. Group 1, the dexmedetomidine group consisted of 67 participants while the 
remaining 75 participants were placed in group 2, the remifentanil group. Following 
cardiac surgery standardized postoperative sedative protocols were initiated: group 1, 
dexmedetomidine loading dose: 0.5 mcg/kg; maintenance dose: 0.2-0.8 mcg/kg/hr and 
group 2, remifentanil 1,000-2,500 mcg/hr. The prevalence of delirium was estimated 
daily in both groups utilizing the CAM-ICU. The CAM-ICU is considered to be the most 
widely used delirium assessment tool because of its ease of use, reliability, and validity 
(Park et al., 2014). Cardiac surgical procedures performed included: aortic valvuloplasty, 
mitral valvuloplasty, coronary artery bypass graft, and tricuspid annuloplasty. All patients 
underwent cardiac surgery on CPB with a surgical approach utilizing either median 
sternotomy or right thoracotomy. CPB management for all patients included moderate 
hypothermia ranging from 26°C-30°C with bypass flows initiated at a rate of 60 
mL/kg/min.  
 Outcomes of this study by Park et al. (2014) (Appendix B, Table B-1) 
demonstrated that the overall prevalence of delirium during the initial postoperative 
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period (first three days) was 16% (23 of 142), with 8.96% (6 of 67) occurring in the 
dexmedetomidine group and 22.67% (17 of 75) in the remifentanil group, which was 
statistically significant (p = 0.027). According to Park et al. (2014) the initial 
postoperative period was defined as the first 3 days following surgery as previous studies 
have shown that the highest prevalence of POD occurs during that timeframe. The study 
found that the mean length of delirium (days) was slightly shorter in the 
dexmedetomidine group with 3.5 ± 1.87 versus 3.76 ± 4.13 in the remifentanil group, (p 
= 0.882). Time to extubation (hours) was slightly higher in the dexmedetomidine group 
22.72 ± 26.36 compared to the remifentanil group 18.60 ± 19.74, (p = 0.299). ICU LOS 
(hours) was also slightly longer in the dexmedetomidine group 67.71 ± 48.41 as opposed 
to the remifentanil group 61.24 ± 30.57, (p = 0.353). Lastly, hospital LOS (days) was 
examined and was determined to be marginally increased in the dexmedetomidine group 
19.96 ± 11.76 whereas the remifentanil group demonstrated an overall hospital LOS of 
18.37 ± 8.45 (days), (p = 0.364). Additionally, postoperative complications and 
hemodynamic side-effects were statistically insignificant between both groups (Park et 
al., 2014).  
 When evaluating the integrity of the study utilizing the CASP questionnaire 
(Appendix C, Table C-1), it appears that the trial addressed a clearly focused issue, all 
patients involved in the study were randomized, and both groups were similar at the start 
of the trial; aside from the experimental intervention, both groups were treated equally 
throughout the study period however, it was also noted that study personnel, healthcare 
professionals, and patients were not “blinded” to this study. The results of this study can 
be applied to adults undergoing a variety of surgical procedures requiring general 
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anesthesia. This study, however, was noted to have several limitations. The first 
limitation noted was the lack of evaluating long-term neurocognitive effects that delirium 
has on the cardiac ICU patient. Secondly, there are limitations to the generalizability of 
the study results as the experiment was conducted in a single medical facility. Lastly, it 
was possible that POD was underrated because CAM-ICU was estimated only once daily 
for the first 3 days postoperatively (Park et al., 2014). It was concluded that the 
administration of dexmedetomidine as a postoperative sedative was associated with 
significantly lower rates of POD in adult patients undergoing cardiac surgery with CPB 
(Park et al., 2014). 
The prospective, single-blinded, single-center, randomized control trial by Djaiani 
et al. (2016) (Appendix A, Table A-2) evaluated whether the administration of 
dexmedetomidine would reduce the incidence of delirium when compared with propofol 
for postoperative sedation in patients undergoing cardiac surgery with CPB. A total of 
183 patients who underwent cardiac surgery were randomly divided into two groups. 
Group 1, the dexmedetomidine group consisted of 91 participants while the remaining 92 
participants were placed in group 2, the propofol group. Following cardiac surgery 
standardized postoperative sedative protocols were initiated: group 1, dexmedetomidine 
loading dose: 0.4 mcg/kg; maintenance dose: 0.2-0.7 mcg/kg/hr and group 2, propofol 
25-50 mcg/kg/min. The prevalence of delirium was estimated in both groups utilizing the 
CAM-ICU. Assessment was performed preoperatively (baseline) and postoperatively 
every 12 hours or more if warranted by the patient’s condition for the first 5 days 
following surgery (Djaiani et al., 2016). Cardiac surgical procedures performed included: 
coronary revascularization, single-valve repair or replacement, combined coronary 
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revascularization with a valve repair/replacement, multiple valve repairs/replacements, 
and redo-sternotomy. All patients underwent cardiac surgery on CPB. CPB management 
included deep hypothermic circulatory arrest 20°C with bypass flow rates ranging 2.0-2.4 
l/min/m2. 
Outcomes of this study by Djaiani et al. (2016) (Appendix B, Table B-2) 
demonstrated that the overall prevalence of delirium during the initial postoperative 
period (first five days) was 24.6% (45 of 183), with 17.5% (16 of 91) occurring in the 
dexmedetomidine group and 31.5% (29 of 92) in the propofol group, (p = 0.028). 
Differences were calculated utilizing a two-tailed Student’s t-test. The study 
demonstrated that the median (range) length of delirium (days) was significantly shorter 
in the dexmedetomidine group with 2 days (1-4) versus 3 days (1-5) in the propofol 
group, (p = 0.04). Median time to extubation (hours) was also significantly lower in the 
dexmedetomidine group 5.5 hours (3.5-14.2) compared to the propofol group 7.6 hours 
(3.8-202.2), (p = 0.0007). ICU LOS (hours) was also decreased, but not significantly in 
the dexmedetomidine group 67.8 (20-214) as opposed to the propofol group 76.5 (17.8-
956.5), (p = 0.38). Lastly, median hospital LOS (days) was examined and was determined 
to be decreased in the dexmedetomidine group 7.5 (5-32) whereas the propofol group 
demonstrated an overall hospital LOS of 10 days (6-74), (p = 0.054). Additionally, the 
overall incidence of postoperative complications, requirement for inotropic support, and 
hemodynamic side-effects were similar between both groups (Djaiani et al., 2016). 
When evaluating the integrity of the study utilizing the CASP questionnaire 
(Appendix C, Table C-2), it appears that the trial addressed a clearly focused issue. All 
patients involved in the study were randomized and both groups were similar at the start 
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of the trial. Aside from the experimental intervention, both groups were treated equally 
throughout the study period however, it was also noted that this was a single-blinded 
study. Therefore, while lack of blinding of dexmedetomidine and propofol infusions was 
identified for healthcare personnel only, testers of CAM-ICU were unaware of study 
objectives (Djaiani et al., 2016). The results of this study can be applied to adults 
undergoing a variety of surgical procedures requiring general anesthesia. This study 
however was noted to have several limitations. The first limitation noted was the lack of 
blinding of the dexmedetomidine and propofol infusions. Secondly, there are limitations 
to the generalizability of the study results as the experiment was conducted in a single 
medical center. Lastly, the dexmedetomidine infusion was limited to the first 24 hours 
only and if patients required sedation beyond that time then the infusion was switched to 
propofol, thus potentially delaying the onset of delirium in the dexmedetomidine group 
(Djaiani et al., 2016). At the completion of the study, Djaiani et al. (2016) concluded that 
the administration of dexmedetomidine as a postoperative sedative was associated with 
significantly lower rates, delayed onset, and shortened duration of POD in adult patients 
undergoing cardiac surgery with CPB.  
The single-center, randomized, prospective study by Maldonado et al. (2009) 
(Appendix A, Table A-3) evaluated whether the use of dexmedetomidine was associated 
with a lower incidence of delirium when compared with the current postoperative 
sedative protocol of either propofol or midazolam in patients undergoing cardiac surgery 
with CPB. A total of 90 patients who underwent cardiac surgery were divided equally 
into three groups. Following cardiac surgery standardized postoperative sedative 
protocols were initiated: group 1, dexmedetomidine loading dose: 0.4 mcg/kg; 
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maintenance dose: 0.2-0.7 mcg/kg/hr, group 2, propofol 25-50 mcg/kg/hr, and group 3, 
midazolam 0.5-2 mg/hr. The prevalence of delirium was estimated daily in all groups 
utilizing the DSM-IV-TR. Cardiac surgical procedures performed included: mitral valve 
repair/replacement, aortic valve repair/replacement, coronary artery bypass graft, aortic 
root replacement, and ascending aortic replacement. All patients underwent cardiac 
surgery on CPB with a surgical approach via a median sternotomy. CPB management 
included moderate hypothermia ranging from 28°C-30°C with bypass flows maintained 
between 2.0-2.4 L/min/mP2P.  
Outcomes of this study by Maldonado et al. (2009) (Appendix B, Table B-3), 
demonstrated that the overall prevalence of delirium during the initial postoperative 
period (first three days) was 34% (31 of 90), with 3% (1 of 30) occurring in the 
dexmedetomidine group, 50% (15 of 30) occurring in the propofol group, and 50% (15 of 
30) occurring in the midazolam group, which was statistically significant (p < 0.001). 
According to Maldonado et al., (2009) the initial postoperative period was defined as the 
first 3 days postoperatively as previous studies have identified that the highest incidence 
of POD occurs during that period. The study demonstrated that the mean length of 
delirium (days) was slightly shorter in the dexmedetomidine group with 2.0 days, versus 
3.0 days in the propofol group and 5.4 days in the midazolam group, (p = 0.82). Time to 
extubation (hours) was slightly higher in the dexmedetomidine group 11.9 hours 
compared to the propofol group 11.1 hours, but lower when compared to the midazolam 
group 12.7 hours, (p = 0.64). ICU LOS (days) was also shorter in the dexmedetomidine 
group 1.9 days as opposed to the propofol group 3.0 days and midazolam group 3.0 days, 
(p = 0.11). Lastly, hospital LOS (days) was examined and was determined to be 
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decreased in the dexmedetomidine group 7.1 days versus 8.2 days in the propofol group 
and 8.9 days in the midazolam group, (p = 0.39).  
When evaluating the integrity of the study utilizing the CASP questionnaire 
(Appendix C, Table C-3), it appears that the trial addressed a clearly focused issue. All 
patients involved in the study were randomized, and all 3 groups were divided equally at 
the start of the trial. Additionally, aside from the experimental intervention, all groups 
were treated equally throughout the study period. However, it was noted that study 
personnel, healthcare professionals, and patients were not “blinded” to this study due in 
part to the milky-white physical characteristic of propofol (Maldonado et al., 2009). The 
results of this study can be applied to adults undergoing a variety of surgical procedures 
requiring general anesthesia. This study, however, was noted to have several limitations. 
The first limitation noted was the lack of blinding of the dexmedetomidine, propofol, and 
midazolam infusions primarily due to the physical characteristics of the medications.  
Secondly, there are limitations to the generalizability of the study results as the 
experiment was conducted in a single medical center, and lastly, there was a dropout rate 
of 24% (28/118). However, no particular group was favored by the number of patients 
excluded (Maldonado et al., 2009). Upon completion of the study, Maldonado et al. 
(2009) concluded that the administration of dexmedetomidine as a postoperative sedative 
was associated with lower rates of POD in adult patients undergoing cardiac surgery with 
CPB.  
The single-center, double-blinded, randomized controlled clinical trial by Shehabi 
et al. (2009), (Appendix A, Table A-4) assessed the effect of dexmedetomidine when 
compared to a morphine-based regimen at equivalent levels of sedation and analgesia, on 
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the prevention of delirium in patients undergoing cardiac surgery on CPB. A total of 299 
patients who underwent cardiac surgery were divided into two groups. Group 1, the 
dexmedetomidine group consisted of 152 participants while the remaining 147 
participants were placed in group 2, the morphine group. Following cardiac surgery 
standardized postoperative sedative protocols were initiated: group 1, dexmedetomidine 
loading dose: none; maintenance dose: 0.1-0.7 mcg/kg/hr and group 2, morphine 10-70 
mcg/kg/hr. The prevalence of delirium was estimated daily in both groups utilizing the 
CAM-ICU. Cardiac surgical procedures performed include: CABG, valve replacement 
procedure, and combination CABG and valve replacement procedure. All patients 
underwent cardiac surgery on CPB. Standard, nonpulsatile CPB management with cold 
blood cardioplegia was utilized while MAP (mean arterial pressure) was maintained 
between 50-70 mmHg with bypass flow rate of 2.4 l/min/m2. 
Outcomes of this study by Shehabi et al. (2009) (Appendix B, Table B-4) 
demonstrated that the overall incidence of delirium during the initial postoperative period 
(first five days) was 11.7% (35 of 299), with 8.6% (13 of 152) occurring in the 
dexmedetomidine group and 15% (22 of 147) in the morphine group, (p = 0.088). The 
study demonstrated that the mean length of delirium (IQR-interquartile range) was 
significantly shorter in the dexmedetomidine group with 2 days (1-7) versus 5 days (2-
12) in the morphine group, (p = 0.031). Mean time to extubation (hours) was also 
significantly lower in the dexmedetomidine group 14 hours (10-18.5) compared to the 
morphine group 15 hours (10-22), (p = 0.036). ICU LOS (hours) was similar in both 
groups with 45 hours (24-71) in the dexmedetomidine group and 45 hours (24-75) in the 
morphine group, (p = 0.148). Lastly, mean hospital LOS (days) was examined and was 
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determined to be identical in both groups at 8 days (7-11), (p = 0.501). Additionally, 
requirement for vasopressor and inotropic support were similar between both groups, 
however the incidence of bradycardia was higher in the dexmedetomidine group, whereas 
the occurrence of hypotension was greatest in the morphine group (Shehabi et al., 2009). 
When evaluating the integrity of the study utilizing the CASP questionnaire 
(Appendix C, Table C-4), it appears that the trial addressed a clearly focused issue. All 
patients involved in the study were randomized, and both groups were similar at the start 
of the trial. Additionally, aside from the experimental intervention, both groups were 
treated equally throughout the study period. Healthcare professionals, patients, and study 
personnel were “blinded” to the treatment. The results of this study can be applied to 
adults undergoing a variety of surgical procedures requiring general anesthesia. This 
study however was noted to have several limitations. The first limitation noted was lack 
of cerebral perfusion monitoring. Secondly, there are limitations to the generalizability of 
the study results as the experiment was conducted in a single medical facility, CAM-ICU 
was performed during the first 5 days only, and the open-label use of morphine in the 
dexmedetomidine group, although this was noted to take place in a small number of 
participants (Shehabi et al., 2009). At the completion of the study, Shehabi et al. (2009) 
concluded that the administration of dexmedetomidine as a postoperative sedative did not 
reduce the occurrence of POD, however, it was shown to dramatically decrease the 
duration of delirium, promote early extubation, and attain adequate sedation and 
analgesia without increasing hypotension in adult patients undergoing cardiac surgery 
with CPB.  
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The two-center, double-blinded, placebo-controlled, randomized clinical trial by 
Li et al. (2017) (Appendix A, Table A-5) investigated the perioperative effects of 
dexmedetomidine administration on the incidence of postoperative delirium in elderly 
patients undergoing cardiac surgery. A total of 285 patients who underwent cardiac 
surgery were divided into two groups. Group 1, the dexmedetomidine group consisted of 
142 participants while the remaining 143 participants were placed in group 2, the normal 
saline (control group). Following cardiac surgery standardized postoperative sedative 
protocols were initiated: group 1, dexmedetomidine OR loading dose: 0.6 mcg/kg (1st 10 
mins) followed by 0.4 mcg/kg/hr intra-operatively, maintenance dose: 0.1 mcg/kg/hr until 
end of mechanical ventilation. Group 2, normal saline: no administration protocol 
followed. The prevalence of delirium was estimated daily in both groups utilizing the 
CAM-ICU. Cardiac surgical procedures performed included: CABG, valve replacement 
procedure (single or multiple), and combination CABG and valve replacement procedure. 
CPB with AOC (aortic cross-clamp). Hypothermia management was not a requirement 
and was utilized in 58% of the cardiac surgical procedures performed.  
Outcomes of this study by Li et al., (2017) (Appendix B, Table B-5) demonstrated 
that the overall prevalence of delirium during the initial postoperative period (first five 
days) was 6.67% (18 of 285), with 4.9% (7 of 142) occurring in the dexmedetomidine 
group and 7.7% (11 of 143) in the control group. The study demonstrated that the mean 
length of delirium (days) was equal in both groups with 2 days (1-3) in the 
dexmedetomidine group and 2 days (1-4) in the control group. Mean time to extubation 
(hours) was again similar in both groups with 15.0 hours (13.7-16.3) in the 
dexmedetomidine group compared to 15.0 hours (13.9-16.1) in the control group. ICU 
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LOS (hours) was also comparable in both groups with 45 hours (43.5-46.5) in the 
dexmedetomidine group and 46 hours (44.8-47.2) in the control group. Lastly, mean 
hospital LOS (days) was examined and there were no differences determined between 
groups at 9 days (8-10). Additionally, the number of patients needing treatment 
intraoperatively for tachycardia was decreased in the dexmedetomidine group, whereas 
the incidence of hypotension intraoperatively requiring treatment was lower in the control 
group (Li et al., 2017).   
When evaluating the integrity of the study utilizing the CASP questionnaire 
(Appendix C, Table C-5), it appears that the trial addressed a clearly focused issue. All 
patients involved in the study were randomized and both groups were similar at the start 
of the trial. Aside from the experimental intervention, both groups were treated equally 
throughout the study period. Healthcare professionals, patients, and study personnel were 
“blinded” to the treatment. The results of this study can be applied to adults undergoing a 
variety of surgical procedures requiring general anesthesia. This study however was 
noted to have several limitations. The first limitation noted was the exclusion of patients 
at high-risk for developing POD (visual/auditory dysfunction, psychiatric disorder, 
language barrier, and liver/renal impairment). Secondly, CAM-ICU was performed once 
daily during the first 5 days only, potentially underestimating the number of patients 
exhibiting delirious symptoms. Lastly, due to the low occurrence of delirium in the 
control group, the trial was considered underpowered to identify discrepancies between 
the two groups (Li et al., 2017). At the completion of the study, Li et al. (2017) concluded 
that the administration of dexmedetomidine as a postoperative sedative did not reduce the 
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occurrence of POD, however, it was shown to decrease the occurrence of intraoperative 
tachycardia in adult patients undergoing cardiac surgery. 
The single-center, retrospective, cohort study by Wanat et al. (2014), (Appendix 
A, Table A-6) evaluated the duration (hours) of mechanical ventilation following cardiac 
surgery in patients receiving dexmedetomidine versus propofol for sedation as a primary 
endpoint, as well as the incidence of postoperative delirium, ICU LOS, hospital LOS, and 
requirement of a secondary sedative in patients receiving dexmedetomidine versus 
propofol for sedation following cardiac surgery as a secondary endpoint. A total of 352 
patients who underwent cardiac surgery were divided into two groups. Group 1, the 
dexmedetomidine group consisted of 33 participants while the remaining 319 participants 
were placed in group 2, the propofol group. Following cardiac surgery, standardized 
postoperative sedative protocols were initiated: group 1, dexmedetomidine loading dose: 
none; maintenance dose: 0.4-0.6 mcg/kg/hr and group 2, propofol 30-50 mcg/kg/hr. The 
prevalence of delirium was estimated daily in both groups utilizing the CAM-ICU. 
Cardiac surgical procedures performed included: CABG, CABG with aortic valve 
surgery, CABG with mitral valve surgery, aortic valve surgery only, and mitral valve 
surgery only.  
Outcomes of this study by Wanat et al. (2014) (Appendix B, Table B-6) 
demonstrated overall prevalence of delirium during the initial postoperative period was 
7.67% (27 of 352), with 9.09% (3 of 33) occurring in the dexmedetomidine group and 
7.53% (24 of 319) in the propofol group, with a (p = 0.747). The authors determined that 
the requirement of a second sedative agent was decreased in the dexmedetomidine group 
with 8 (24.2%) versus 86 (27.0%) in the propofol group, (p = 0.737). Time to extubation 
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(hours) was significantly decreased in the dexmedetomidine group 7.37 ± 4.30 compared 
to the propofol group 12.88 ± 15.42, (p = 0.042). ICU LOS (days) was somewhat 
decreased in the dexmedetomidine group 2.55 ± 2.95 as opposed to the propofol group 
3.99 ± 4.78, (p = 0.091). Lastly, hospital LOS (days) was examined and was determined 
to be decreased in the dexmedetomidine group 9.79 ± 6.77 whereas the propofol group 
demonstrated an overall hospital LOS of 12.42 ± 7.44 (days), (p = 0.052).  
 When evaluating the integrity of the study utilizing the CASP questionnaire 
(Appendix C, Table C-6), it appears that the trial addressed a clearly focused issue. This 
was a retrospective study, therefore, all patients involved in the study were not 
randomized. At the start of the trial, it was found that both groups were not similar in 
size. All participants were properly accounted for at its conclusion. It is difficult to 
surmise if aside from the experimental intervention whether both groups were treated 
equally throughout the study period. Again, because this study was retrospective in 
nature, study personnel, healthcare professionals, and patients were not “blinded.” The 
results of this study can be applied to adults undergoing a variety of surgical procedures 
requiring general anesthesia. This study however was noted to have several limitations. 
The first limitation noted was that specific medication side effects were not documented; 
secondly, the large discrepancy among the number of patients who received 
dexmedetomidine versus the number of patients who received propofol; and lastly, lack 
of randomization (Wanat et al., 2014). Failure to randomize potentially led to patients 
being prescribed a sedative based on physician preference, therefore potentially 
producing a source of bias (Wanat et al., 2014).  It was concluded at the completion of 
the study that the administration of dexmedetomidine as a postoperative sedative was 
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associated with a significant reduction of mechanical ventilation time, however, no 
difference was noted regarding the incidence of delirium between both study groups 
(Wanat et al., 2014). 
Cross-Study Analysis 
 The cross-study analysis table (Appendix D) demonstrates the postoperative 
sedative protocol initiated for each study, as well as the major outcomes investigated 
including: incidence of delirium, mean length of delirium, time to extubation, ICU LOS, 
and hospital LOS. There was one study by Wanat et al. (2014) that did not measure mean 
length of delirium as a variable. Wanat et al. did, however, investigate the requirement of 
an additional sedative agent and noted that the incidence was decreased in the 
dexmedetomidine group (8) when compared with the propofol group (86).   
 All sedative protocols consisted of dexmedetomidine as the main sedative agent 
and was compared against Remifentanil (study 1), propofol (study 2, 3, and 6), 
midazolam (study 3), morphine (study 4), and normal saline (study 5).  Overall, the 
incidence of delirium was decreased in the dexmedetomidine groups (study 1, 2, 3, 4, and 
5), but was higher in study 6 when compared to the propofol group. Mean length of 
delirium was also found to be decreased in the dexmedetomidine groups (study 1,2, 3, 
and 4), but was equal when compared with normal saline group (study 5) and was not a 
variable examined in study 6. Time to extubation was found to decreased in the 
dexmedetomidine groups (study 2, 3, 4, and 6), whereas it was increased when compared 
to remifentanil (study 1), propofol (study 3), and equal to normal saline (study 5). ICU 
LOS was decreased in the dexmedetomidine groups (study 2, 3, 5, and 6), but was 
increased when compared to remifentanil (study 1), yet equal when compared to 
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morphine (study 4). Lastly, hospital LOS was decreased in the dexmedetomidine groups 
(study 2, 3, and 6), yet increased when compared with remifentanil (study 1), and equal 
when compared with morphine (study 4) and normal saline (study 5).  
Next, the summary and conclusions will be presented.  
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Summary and Conclusions 
POD is a major complication following surgery and is considered the most 
common complication among older adults following cardiac surgery with up to 87% of 
patients being affected (Whitlock et al., 2011). The untoward effects of POD are 
characterized as restlessness, agitation, combativeness, hallucinations, irritability, and 
confusion. These consequences place patients and medical personnel in potentially 
precarious situations. This troublesome behavior is both distressing and perplexing to 
patients and their loved ones. Furthermore, the risk of mortality increases 10-20% for 
every forty-eight hours that a patient remains in a delirious state following cardiac 
surgery (Whitlock et al., 2011). POD increases the duration of mechanical ventilation, 
increases both ICU and overall hospital length of stay, decreases patient functional status, 
and increases the risk of mortality. The use of antihistamines, benzodiazepines, muscle 
relaxants, and meperidine (often used to treat postoperative shivering) should be avoided 
in this vulnerable population (Whitlock et al., 2011).  
Dexmedetomidine, a highly selective α2 agonist, inhibits the release of 
norepinephrine presynaptically causing analgesia and inhibits central nervous system 
stimulation in the postsynaptic neurons causing decreased blood pressure and heart rate; 
together, contributing to the effects of analgesia, anesthesia, and sedation (Naaz &Ozair, 
2014). Benefits of dexmedetomidine for sedation include the promotion of a biological 
sleep pattern, production of minimal respiratory depression, and its association with 
decreased narcotic use (Maldonado et al., 2009).  
The purpose of this systematic review was to investigate whether 
dexmedetomidine decreases the occurrence of POD in the adult cardiac surgical 
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population. A comprehensive literature review was completed using CINAHL, PubMed, 
and Medline focusing on the pathology of postoperative delirium, the physiology of 
cardiac surgery, and the pharmacodynamics of dexmedetomidine. A dual theoretical 
framework was chosen to assist in the identification of eligible studies based on inclusion 
criteria. PRISMA was the primary framework utilized for this systematic review and 
consists of a 27-item checklist and four-phase flowchart. Additionally, the multifactorial 
model by Inouye and Charpentier was also utilized. The multifactorial model describes 
four axes that explain the complex relationship between baseline vulnerability or 
predisposing factors; and precipitating factors or noxious insults contributing to the 
development of delirium (Inouye & Charpentier, 1996). 
Individual study analysis was completed on the final six studies that met inclusion 
criteria. Study specific data tables were created identifying key information pertinent to 
each study. Data outcome tables were then created to determine the effect of 
dexmedetomidine on postoperative delirium following cardiac surgery. Next, critical 
appraisal of individual RCTs was performed utilizing the Critical Appraisal Skills 
Programme (CASP) checklist. Lastly, a cross study analysis table was created comparing 
the postoperative sedative protocol initiated, the incidence of delirium, the duration of 
delirium, time to extubation, ICU LOS, and overall hospital LOS among the six studies 
selected. 
The use of dexmedetomidine as a postoperative sedative is becoming increasingly 
popular, particularly among ICU and anesthesia providers. Due to its highly selective α2 
properties, dexmedetomidine provides patients the benefits of pain control and anxiolysis 
with minimal respiratory depression, thus making it a frontrunner for fragile patient 
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populations. However, dexmedetomidine does not come without its share of potential 
adverse effects. Dexmedetomidine has been associated with hypotension at low 
concentrations and hypertension at high concentrations; therefore, it is considered to have 
a biphasic effect on blood pressure. One of the most notable adverse effects is transient 
bradycardia which can be exaggerated with rapid infusion or bolus.   
There were several limitations identified when completing this systematic review. 
Lack of blinding was a limitation noted in some studies. Two of the studies included in 
the systematic review were double-blinded; one was single-blinded; and the remaining 
three were not blinded. Another limitation noted was the length of time that certain 
studies allowed patients to remain on a dexmedetomidine infusion. One study in 
particular transitioned patients who required intubation greater than 24 hours from a 
dexmedetomidine infusion to a propofol infusion; therefore, potentially affecting study 
results. Additionally, delirium assessment was performed once per day for the 
postoperative period defined by that study’s designers. Some studies defined the initial 
postoperative period as the first three days; whereas other studies identified the 
postoperative period as the first five days. Delirium that occurred after that initial 
postoperative period was not included thus potentially affecting study results. Lastly, the 
lack of a definitive preoperative cognitive screening tool to assess patients at risk for 
postoperative cognitive dysfunction was also noted to be lacking in some studies. 
The findings of this systematic review determined that in the adult cardiac 
surgical population, dexmedetomidine was associated with a decreased incidence of 
POD. Additionally, of those that did develop POD, the mean length of delirium was 
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decreased in the dexmedetomidine group. Lastly, the results for time to extubation, ICU 
LOS, and hospital LOS varied amongst the six studies examined.    
Next, the recommendations and implications for advanced nursing practice will 
be presented.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
48 
 
Recommendations and Implications for Advanced Nursing Practice 
 With the induction of general anesthesia for cardiac surgery, patients succumb to 
the multitude of anesthetic agents administered to them. It is of paramount importance for 
the anesthesia provider to ensure that medications are administered to the patient based 
on necessity and not on habit alone. Often, medications administered during induction 
can render side effects lasting beyond the perioperative period. Potential triggers of 
postoperative delirium that can occur during the perioperative period include 
hypotension, hypoxemia, electrolyte imbalances, pain, sepsis, and alcohol/drug 
withdrawal (Mantz, Hemmings, & Boddaert, 2010). It is imperative that the anesthesia 
provider heed the slightest changes during the operative period and intervene 
appropriately in order to avert potentially devastating outcomes.  
 A study by Riker et al. (2009), found that patients who were sedated with 
dexmedetomidine spent significantly less time on mechanical ventilation and developed 
less delirium when compared to midazolam, a benzodiazepine. This study and others like 
it provide a viable option in the selection of postoperative sedatives for mechanically 
vented patients following cardiac surgery. The anesthesia provider should initiate the 
dexmedetomidine infusion in the operating room prior to patient transfer of care to the 
ICU, thus allowing for maximum benefit and efficacy. Avoiding medications such as 
benzodiazepines in the older population during the perioperative period has also been 
shown to decrease the incidence of POD. Medications are one of the most common 
causes of postoperative delirium and are also the most treatable (Mantz et al., 2010). 
Avoiding polypharmacy, particularly in the elderly population decreases the incidence of 
POD significantly. Educating anesthesia providers and advanced practice nurses 
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concerning this significant predicament is essential. Additionally, educating providers 
regarding the multifactorial components associated with the development of POD is 
crucial for prevention or at a minimum decreasing the severity of cognitive dysfunction. 
According to Mantz et al., (2010), sleep deprivation is a major contributor to the 
development of POD, thus it is essential to avoid unnecessary disturbances to the 
postoperative patient particularly during periods of rest or while asleep. Additionally, the 
use of dexmedetomidine is known to resemble a natural sleep pattern, therefore it is a 
frontrunner for cardiac surgery patients requiring sedation, anxiolysis, and pain relief 
with minimal respiratory depression.  
 Prevention is key! Minimizing risk factors, identifying at risk patients, early 
recognition, and swift intervention are all crucial steps necessary to avoid untoward 
sequela of POD. Although anesthesia providers have limited interaction with the surgical 
patient prior to surgery; thorough pre-admission testing including identification of at-risk 
or high-risk patients should be determined by the APRN and must be communicated with 
the patient care team. Collaboration between the surgeon, anesthesia provider, and 
healthcare team is necessary when an at-risk or high-risk patient is identified. Providing a 
seamless transition for patients from one care team to the next prior to and throughout 
their surgical process is paramount to ensure that gaps and possibly misdiagnosis of POD 
is averted. Continuity of care is essential to providing this seamless transition beginning 
with thorough preoperative testing, continuing through the perioperative period, 
progressing through recovery, and culminating with patient discharge. This partnership 
among healthcare providers allows for optimal patient care and satisfactory outcomes. 
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Appendix A 
Table A-1 
 
Study Specific Data 
 
Study 1: Park, J. B., Bang, S. H., Chee, H. K., Kin, J. S., Lee, S. A., & Shin, J. K. (2014). Efficacy and safety of dexmedetomidine for 
postoperative delirium in adult cardiac surgery on cardiopulmonary bypass. The Korean Journal of Thoracic and Cardiovascular 
Surgery, 47(3), 249-254. 
 
Aim 
 
Investigate the 
postoperative 
sedative effects of 
dexmedetomidine 
associated with a 
lower incidence of 
delirium, compared 
with the current 
postoperative 
sedative protocol 
of remifentanil in 
patients 
undergoing open-
heart surgery with 
CPB. 
Design 
 
Single-center, 
randomized, 
prospective study. 
 
Group 1-  
dexmedetomidine 
 
Group 2-  
remifentanil  
Site 
 
Konkuk 
University 
Medical Center, 
Department of 
Thoracic and 
Cardiovascular 
Surgery; Seoul, 
Korea. 
Sample 
 
142 patients who 
underwent cardiac 
surgery were 
divided into two 
groups. 
 
Group 1 (n=67) 
dexmedetomidine 
 
Group 2 (n=75) 
remifentanil  
 
All patients 
underwent cardiac 
surgery on CPB. 
Method  
 
Postoperative sedative 
protocol initiated: 
 
Group 1- 
dexmedetomidine 
loading dose: 0.5 
mcg/kg; maintenance 
dose: 0.2-0.8 
mcg/kg/hr. 
 
Group 2- 
remifentanil 1,000-
2,500 mcg/hr. 
 
Prevalence of delirium 
estimated daily via the 
CAM-ICU. 
Procedure 
 
AVP only, AVP with 
MVP, AVP with CABG, 
MVP only, and MVP 
with TA.  
 
Surgical approach 
utilizing either median 
sternotomy or right 
throracotomy in 
conjunction with CPB. 
 
CPB management 
included moderate 
hypothermia ranging 
from (26°C-30°C) with 
bypass flows initiated at 
a rate of 60 mL/kg/min. 
 
Note. CPB-cardiopulmonary bypass, AVP-aortic valvuloplasty, MVP-mitral valvuloplasty, CABG-coronary artery bypass graft, TA-
tricuspid annuloplasty, CAM-ICU-confusion assessment method for the intensive care unit   
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Appendix A 
Table A-2 
 
Study Specific Data 
 
Study 2: Djaiani, G., Silverton, N., Fedorko, L., Carroll, J., Styra, R., Rao, V., & Katznelson, R. (2015). Dexmedetomidine versus 
propofol sedation reduces delirium after cardiac surgery: A randomized controlled trial. American Society of Anesthesiologists, 124 (2), 
362-368. 
Aim 
 
Investigate whether 
the administration of 
dexmedetomidine 
would reduce the 
incidence of 
delirium when 
compared with 
propofol for 
postoperative 
sedation in patients 
undergoing cardiac 
surgery with CPB. 
Design 
 
A prospective, 
randomized, 
single-blinded, 
single-centered, 
controlled 
clinical trial. 
 
Group 1-  
dexmedetomidine 
 
Group 2-  
propofol  
 
Site 
 
Toronto General 
Hospital, 
University Health 
Network, 
Department of 
Anesthesia and 
Pain Management, 
Division of 
Cardiovascular 
Surgery; Toronto, 
Ontario, Canada. 
 
Sample 
 
183 patients who 
underwent cardiac 
surgery were 
randomly divided 
into two groups. 
 
Group 1 (n=91) 
dexmedetomidine 
 
Group 2 (n=92) 
propofol  
 
All patients 
underwent cardiac 
surgery on CPB.  
Method  
 
Postoperative sedative 
protocol initiated: 
 
Group 1- 
dexmedetomidine 
loading dose: 0.4 
mcg/kg; maintenance 
dose: 0.2-0.7 
mcg/kg/hr. 
 
Group 2- 
propofol 25-50 
mcg/kg/min. 
 
Presence of delirium 
estimated daily via 
the CAM-ICU. 
Procedure 
 
Coronary 
revascularization, single-
valve repair or 
replacement, combined 
coronary revascularization 
with a valve 
repair/replacement, 
multiple valve 
repairs/replacements, redo-
sternotomy.   
 
CPB management included 
deep hypothermic 
circulatory arrest (20°C) 
with bypass flow rates 
ranging 2.0-2.4 l/min/m2. 
Note. CPB-cardiopulmonary bypass, CAM-ICU-confusion assessment method for the intensive care unit   
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Appendix A 
Table A-3 
 
Study Specific Data 
 
Study 3: Maldonado, J. R., Wysong, A., Van Der Starre, P. J. A., Block, T., Miller, C., & Reitz, B. A. (2009). Dexmedetomidine and the 
reduction of postoperative delirium after cardiac surgery. Psychosomatics, 50(3), 206-217. 
Aim 
 
Investigate whether 
the use of 
dexmedetomidine (a 
selective α2-
adrenergic receptor-
agonist with analgesic, 
sedative, and 
antinociceptive 
effects) was associated 
with a lower incidence 
of delirium when 
compared with the 
current postoperative 
sedative protocol of 
either propofol or 
midazolam in patients 
undergoing cardiac 
surgery with CPB. 
Design 
 
Single-center, 
randomized, 
prospective 
study. 
 
Group 1-  
dexmedetomidine 
 
Group 2-  
propofol 
 
Group 3- 
midazolam   
Site 
 
Stanford 
University School 
of Medicine, 
Department of 
Psychiatry and 
Behavioral 
Sciences, 
Department of 
Anesthesiology, 
and the 
Department of 
Cardiovascular 
Surgery; Stanford, 
California. 
Sample 
 
90 patients who 
underwent cardiac 
surgery were 
divided equally 
into three groups. 
 
Group 1 (n=30) 
dexmedetomidine 
 
Group 2 (n=30) 
propofol 
 
Group 3 (n=30) 
midazolam 
 
All patients 
underwent cardiac 
surgery on CPB. 
Method  
 
Postoperative sedative 
protocol initiated: 
 
Group 1- 
dexmedetomidine 
loading dose: 0.4 
mcg/kg; maintenance 
dose: 0.2-0.7 mcg/kg/hr. 
 
Group 2- 
propofol 25-50 
mcg/kg/min. 
 
Group 3-midazolam 0.5-
2 mg/hr. 
 
Prevalence of delirium 
estimated daily via the 
DSM-IV-TR. 
Procedure 
 
MVR, AVR, MVR & 
AVR, aortic root 
replacement, 
ascending aortic 
replacement, and 
CABG 
 
Surgical approach via 
median sternotomy in 
conjunction with CPB. 
 
CPB management 
included moderate 
hypothermia ranging 
from (28°C-30°C) 
with bypass flows 
maintained between 
(2.0-2.4 L/min/mP2P).   
 
Note. CPB-cardiopulmonary bypass, MVR-mitral valve repair/replacement, AVR-aortic valve repair/replacement, CABG-coronary 
artery bypass graft, DSM-IV-TR-Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (Text Revision)   
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Appendix A 
Table A-4 
 
Study Specific Data 
 
Study 4: Shehabi, Y., Grant, P., Wolfenden, H., Hammond, N., Bass, F., Campbell, M., & Chen, J. (2009). Prevalence of delirium with 
dexmedetomidine compared with morphine based therapy after cardiac surgery: A randomized controlled trial (dexmedetomidine 
compared to morphine-DEXCOM study). Anesthesiology, 111(5), 1075-1084.  
 
Aim 
 
To assess the effect 
of dexmedetomidine 
(an α2 agonist) when 
compared to a 
morphine-based 
regimen at 
equivalent levels of 
sedation and 
analgesia, on the 
prevention of 
delirium in patients 
undergoing cardiac 
surgery.  
Design 
 
Single-center, 
randomized, 
double-blinded, 
controlled clinical 
trial. 
 
Group 1-  
dexmedetomidine 
 
Group 2-  
morphine 
Site 
 
Prince of Wales 
Hospital, Division 
of Cardiac and 
Critical Care 
Services, Clinical 
Program of Acute 
Care; Sydney, 
Australia. 
Sample 
 
299 patients who 
underwent cardiac 
surgery were 
divided into two 
groups. 
 
Group 1 (n=152) 
dexmedetomidine 
 
Group 2 (n=147) 
morphine  
 
All patients 
underwent cardiac 
surgery on CPB. 
Method  
 
Postoperative sedative 
protocol initiated: 
 
Group 1- 
dexmedetomidine 
loading dose: none 
maintenance dose: 0.1-
0.7 mcg/kg/hr. 
 
Group 2- 
morphine 10-70 
mcg/kg/hr. 
 
Prevalence of delirium 
estimated daily via the 
CAM-ICU. 
Procedure 
 
CABG, valve 
replacement procedure, 
combination CABG and 
valve replacement 
procedure.  
 
Standard, nonpulsatile 
CPB management with 
cold blood cardioplegia 
was utilized. MAP 
maintained between 50-
70 mmHg with bypass 
flow rate of 2.4 l/min/m2. 
Note. CPB-cardiopulmonary bypass, CABG-coronary artery bypass graft, CAM-ICU-confusion assessment method for the intensive 
care unit, MAP-mean arterial pressure    
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Appendix A 
Table A-5 
 
Study Specific Data 
 
Study 5: Li, X., Yang, J., Nie, X. L., Zhang, Y., Li, X. Y., Li, L. H., Wang, D. X., & Ma, D. (2017). Impact of dexmedetomidine on the 
incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS ONE, 12(2), 1-15. 
Aim 
 
Investigate the 
perioperative 
effects of 
dexmedetomidine 
administration on 
the incidence of   
postoperative 
delirium in elderly 
patients undergoing 
cardiac surgery.   
Design 
 
Randomized, 
double-blinded, 
placebo-
controlled, two-
centered clinical 
trial. 
 
Group 1-  
dexmedetomidine 
 
Group 2-  
normal saline   
Site 
 
Peking University 
First Hospital, 
Department of 
Anesthesiology and 
Critical Care 
Medicine; Beijing, 
China.  
 
Fuwai Hospital, 
National Center for 
Cardiovascular 
Diseases, Department 
of Anesthesiology, 
Chinese Academy of 
Medical Sciences and 
Peking Union Medical 
College; Beijing, 
China. 
 
Sample 
 
285 patients who 
underwent cardiac 
surgery were 
divided into two 
groups. 
 
Group 1 (n=142) 
dexmedetomidine 
 
Group 2 (n=143) 
normal saline 
(control group)   
 
 
Method  
 
Perioperative sedative 
protocol: 
 
Group 1- dexmedetomidine in 
OR: 0.6 mcg/kg (1st 10 mins) 
followed by 0.4 mcg/kg/hr 
intra-op, maintenance dose: 0.1 
mcg/kg/hr until end of 
mechanical ventilation. 
 
Group 2- 
normal saline  
no administration protocol 
followed. 
 
Prevalence of delirium 
estimated daily via the CAM-
ICU. 
Procedure 
 
CABG, valve 
replacement 
(single or 
multiple), CABG 
and valve 
replacement(s).  
 
CPB with AOC 
and hypothermia 
management was 
not a requirement 
and was utilized in 
58% of the cardiac 
surgical 
procedures 
performed.  
 
Note. CABG-coronary artery bypass graft, CAM-ICU-confusion assessment method for the intensive care unit, AOC-aortic cross 
clamping, CPB-cardiopulmonary bypass 
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Appendix A 
Table A-6 
 
Study Specific Data 
 
Study 6: Wanat, M., Fitousis, K., Boston, F., & Masud, F. (2014). Comparison of dexmedetomidine versus propofol for sedation in 
mechanically ventilated patients after cardiovascular surgery. Methodist DeBakey Cardiovascular Journal, 10(2), 111-117. 
 
 
Aim 
 
Primary endpoint: 
Investigate duration (hrs) 
of mechanical ventilation 
following cardiac surgery 
in patients receiving 
dexmedetomidine versus 
propofol for sedation. 
  
Secondary endpoints: 
investigate incidence of 
postoperative delirium, 
ICU LOS, hospital LOS, 
and requirement of a 
secondary sedative in 
patients receiving 
dexmedetomidine versus 
propofol for sedation 
following    
cardiac surgery. 
 
Design 
 
Single-center, 
retrospective, 
cohort study. 
 
Group 1-  
dexmedetomidine 
 
Group 2-  
propofol  
Site 
 
Houston 
Methodist 
Hospital, 
Houston 
Methodist 
DeBakey Heart 
& Vascular 
Center; Houston, 
Texas. 
Sample 
 
352 patients who 
underwent cardiac 
surgery were 
divided into two 
groups. 
 
Group 1 (n=33) 
dexmedetomidine 
 
Group 2 (n=319) 
propofol 
 
 
Method  
 
Postoperative 
sedative protocol 
initiated: 
 
Group 1- 
dexmedetomidine 
0.4-0.6 mcg/kg/hr. 
 
Group 2- 
propofol 30-50 
mcg/kg/hr. 
 
Prevalence of 
delirium estimated 
daily via the CAM-
ICU. 
Procedure 
 
CABG, CABG with 
aortic valve surgery, 
CABG with mitral 
valve surgery, aortic 
valve surgery only, 
mitral valve surgery 
only. 
 
 
 
Note. LOS-length of stay, CABG-coronary artery bypass graft, CAM-ICU-confusion assessment method for the intensive care unit   
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Appendix B 
Table B-1 
 
Outcome Data Collection 
 
Study 1: Park, J. B., Bang, S. H., Chee, H. K., Kin, J. S., Lee, S. A., & Shin, J. K. (2014). Efficacy and safety of dexmedetomidine 
for postoperative delirium in adult cardiac surgery on cardiopulmonary bypass. The Korean Journal of Thoracic and Cardiovascular 
Surgery, 47(3), 249-254. 
Dexmedetomidine (n=67) Remifentanil (n=75) P-value  
 
Incidence of 
delirium 
 
6 (8.96) 
 
17 (22.67) 
 
0.027 
 
Mean length of 
delirium (days) 
 
3.5 ± 1.87 
 
 
3.76 ± 4.13 
 
 
0.882 
 
 
Time to 
extubation (hrs) 
 
 22.72 ± 26.36 
 
 
18.60 ± 19.74 
 
 
0.299 
 
ICU LOS (hrs) 
 
 67.71 ± 48.41 
 
 
 61.24 ± 30.57 
 
 
0.353 
 
Hospital LOS 
(days) 
 
 
19.96 ± 11.76 
 
 
18.37 ± 8.45 
 
 
0.364 
Note. The overall prevalence of delirium during the initial postoperative period (first three days) was 16% (23 of 142), with 8.96% (6 
of 67) occurring in the dexmedetomidine group and 22.67% (17 of 75) in the remifentanil group, with a p value <0.05. P values less 
than 0.05 were recognized as statistically significant. P-values calculated utilizing the Student t-test.  
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Appendix B 
Table B-2 
 
Outcome Data Collection 
 
Study 2: Djaiani, G., Silverton, N., Fedorko, L., Carroll, J., Styra, R., Rao, V., & Katznelson, R. (2015). Dexmedetomidine versus 
propofol sedation reduces delirium after cardiac surgery: A randomized controlled trial. American Society of Anesthesiologists, 124 
(2), 362-368. 
Dexmedetomidine (n=91) Propofol (n=92) P-value  
 
Incidence of 
delirium 
 
16 (17.5) 
 
29 (31.5) 
 
0.028 
 
Duration of 
delirium (days), 
median (range)  
 
 
2 (1-4) 
 
 
 
3 (1-5) 
 
 
 
0.04 
 
 
Time to extubation 
(hrs), median 
(range) 
 
 
 5.5 (3.5-14.2) 
 
 
 
7.6 (3.8-202.2) 
 
 
 
0.0007 
 
ICU LOS (hrs), 
median (range) 
 
 67.8 (20-214) 
 
 
 76.5 (17.8-956.5) 
 
 
0.38 
 
Hospital LOS 
(days), median 
(range) 
 
 
7.5 (5-32) 
 
 
 
10 (6-74) 
 
 
0.054 
Note. The overall prevalence of delirium during the initial postoperative period (first five days) was 24.6% (45 of 183), with 17.5% 
(16 of 91) occurring in the dexmedetomidine group and 31.5% (29 of 92) in the propofol group, with a p value <0.05. P values less 
than 0.05 were recognized as statistically significant. P-values calculated utilizing a two-tailed Student’s t-test.  
63 
 
Appendix B 
Table B-3 
 
Outcome Data Collection 
 
Study 3: Maldonado, J. R., Wysong, A., Van Der Starre, P. J. A., Block, T., Miller, C., & Reitz, B. A. (2009). Dexmedetomidine and 
the reduction of postoperative delirium after cardiac surgery. Psychosomatics, 50(3), 206-217. 
 
Dexmedetomidine (n=30) Propofol (n=30) Midazolam (n=30) P-value  
 
Incidence of 
delirium  
 
1/30 (3%) 
 
15/30 (50%) 
 
15/30 (50%) 
 
<0.001 
 
Mean length of 
delirium (days) 
 
2.0 (0) 
 
3.0 (3.1) 
 
 
5.4 (6.6) 
 
0.82 
 
 
Intubation time 
(hrs) 
 
11.9 (4.5) 
 
 
11.1 (4.6) 
 
 
12.7 (8.5) 
 
0.64 
 
ICU LOS (days) 
 
 1.9 (0.9) 
 
 
 3.0 (2.0) 
 
 
3.0 (3.0) 
 
0.11 
 
Hospital LOS 
(days) 
 
 
7.1 (1.9) 
 
8.2 (3.8) 
 
8.9 (4.7) 
 
0.39 
Note. The overall prevalence of delirium during the initial postoperative period (first three days) was 34% (31 of 90), with 3% (1 of 
30) occurring in the dexmedetomidine group, 50% (15 of 30) occurring in the propofol group, and 50% (15 of 30) occurring in the 
midazolam group, with a p value <0.05. P values less than 0.05 were recognized as statistically significant. P-values calculated 
utilizing independent t-tests.  
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Appendix B 
Table B-4 
 
Outcome Data Collection 
 
Study 4: Shehabi, Y., Grant, P., Wolfenden, H., Hammond, N., Bass, F., Campbell, M., & Chen, J. (2009). Prevalence of delirium 
with dexmedetomidine compared with morphine based therapy after cardiac surgery: A randomized controlled trial 
(dexmedetomidine compared to morphine-DEXCOM study). Anesthesiology, 111(5), 1075-1084.  
 
Dexmedetomidine (n=152) Morphine (n=147) P-value  
 
Incidence of 
delirium (%) 
 
13 (8.6%) 
 
22 (15%) 
 
0.088 
 
Mean length of 
delirium (IQR)  
 
2 [1-7] 
 
 
5 [2-12] 
 
 
0.031 
 
 
Time to extubation 
(hrs) 
 
 14 (10-18.5) 
 
 
15 (10-22) 
 
 
0.036 
 
ICU LOS (hrs) 
 
 45 (24-71) 
 
 
 45 (24-75) 
 
 
0.148 
 
Hospital LOS 
(days) 
 
 
8 (7-11) 
 
 
8 (7-11) 
 
 
0.501 
Note. IQR-interquartile range. The overall incidence of delirium during the initial postoperative period (first five days) was 11.7% (35 
of 299), with 8.6% (13 of 152) occurring in the dexmedetomidine group and 15% (22 of 147) in the morphine group, with a p value of 
0.088. P values less than 0.05 were recognized as statistically significant. P-values calculated utilizing an unpaired Student t-test.  
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Appendix B 
Table B-5 
 
Outcome Data Collection 
 
Study 5: Li, X., Yang, J., Nie, X. L., Zhang, Y., Li, X. Y., Li, L. H., Wang, D. X., & Ma, D. (2017). Impact of dexmedetomidine on 
the incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS ONE, 12(2), 1-15. 
 
Dexmedetomidine (n=142) Normal Saline (n=143) P-value  
 
Incidence of 
delirium 
 
7 (4.9%) 
 
11 (7.7%) 
 
0.341 
 
Mean length of 
delirium (days) 
 
2 (1-3) 
 
 
2 (1-4) 
 
 
0.328 
 
 
Time to 
extubation (hrs) 
 
15.0 (13.7-16.3) 
 
 
15.0 (13.9-16.1) 
 
 
0.044 
 
ICU LOS (hrs) 
 
 45.0 (43.5-46.5) 
 
 
 46.0 (44.8-47.2) 
 
 
0.788 
 
Hospital LOS 
(days) 
 
 
9 (8-10) 
 
 
9 (8-10) 
 
 
0.826 
Note. The overall prevalence of delirium during the initial postoperative period (first five days) was 6.67% (19 of 285), with 4.9% (7 
of 142) occurring in the dexmedetomidine group and 7.7% (11 of 143) in the control group, with a p value of 0.341. P values less than 
0.05 were recognized as statistically significant. P-values calculated utilizing the Student t-test.  
 
 
66 
 
Appendix B 
Table B-6 
 
Outcome Data Collection 
 
Study 6: Wanat, M., Fitousis, K., Boston, F., & Masud, F. (2014). Comparison of dexmedetomidine versus propofol for sedation in 
mechanically ventilated patients after cardiovascular surgery. Methodist DeBakey Cardiovascular Journal, 10(2), 111-117. 
 
Dexmedetomidine (n=33) Propofol (n=319) P-value  
 
Incidence of 
delirium 
 
3 (9.09%) 
 
24 (7.53%) 
 
0.747 
 
Requirement of 
2nd sedative agent 
 
8 (24.2%) 
 
 
86 (27.0%) 
 
 
0.737 
 
 
Time to 
extubation (hrs) 
 
 7.37 ± 4.30 
 
 
12.88 ± 15.42 
 
 
0.042 
 
ICU LOS (days) 
 
  2.55 ± 2.95 
 
 
 3.99 ± 4.78 
 
 
0.091 
 
Hospital LOS 
(days) 
 
 
9.79 ± 6.77 
 
 
12.42 ± 7.44 
 
 
0.052 
Note. The overall prevalence of delirium during the initial postoperative period was 7.67% (27 of 352), with 9.09% (3 of 33) occurring 
in the dexmedetomidine group and 7.53% (24 of 319) in the propofol group, with a p value of 0.747. P values less than 0.05 were 
recognized as statistically significant. P-values calculated utilizing the Student t-test.
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Appendix C 
Table C-1 
 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 1: Park, J. B., Bang, S. H., Chee, H. K., Kin, J. S., Lee, S. A., & Shin, J. K. (2014). 
Efficacy and safety of dexmedetomidine for postoperative delirium in adult cardiac surgery 
on cardiopulmonary bypass. The Korean Journal of Thoracic and Cardiovascular Surgery, 
47(3), 249-254. 
 
A) Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue? X   
2. Was the assignment of patients to treatments 
randomized? 
X   
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “blind” to treatment? 
  X 
5. Were the groups similar at the start of the 
trial? 
X   
6. Aside from the experimental intervention, 
were the groups treated equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
142 cardiac surgical patients  
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Significant decrease in POD in 
dexmedetomidine group  
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your context? 
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and costs?
    
X   
Note. POD-postoperative delirium   
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         Appendix C 
Table C-2 
 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 2: Djaiani, G., Silverton, N., Fedorko, L., Carroll, J., Styra, R., Rao, V., & 
Katznelson, R. (2015). Dexmedetomidine versus propofol sedation reduces delirium after 
cardiac surgery: A randomized controlled trial. American Society of Anesthesiologists, 124 
(2), 362-368. 
 
A) Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue? X   
2. Was the assignment of patients to treatments 
randomized? 
X   
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “blind” to treatment? ** 
X   
5. Were the groups similar at the start of the 
trial? 
X   
6. Aside from the experimental intervention, 
were the groups treated equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
183 cardiac surgical patients  
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Significant decrease in POD in 
dexmedetomidine group vs propofol 
group 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your context? 
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and costs?
    
X   
Note. **Lack of blinding of dexmedetomidine and propofol infusions was identified, however 
testers of CAM-ICU were unaware of study objectives.  
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     Appendix C 
Table C-3 
 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 3: Maldonado, J. R., Wysong, A., Van Der Starre, P. J. A., Block, T., Miller, C., & 
Reitz, B. A. (2009). Dexmedetomidine and the reduction of postoperative delirium after 
cardiac surgery. Psychosomatics, 50(3), 206-217. 
 
A) Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue? X   
2. Was the assignment of patients to treatments 
randomized? 
X   
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “blind” to treatment? 
  X 
5. Were the groups similar at the start of the 
trial? 
X   
6. Aside from the experimental intervention, 
were the groups treated equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
90 cardiac surgical patients  
 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Significant decrease in POD in 
dexmedetomidine group versus propofol 
and midazolam groups  
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your context? 
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and costs?
    
X   
Note. POD-postoperative delirium   
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       Appendix C   
Table C-4 
 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 4: Shehabi, Y., Grant, P., Wolfenden, H., Hammond, N., Bass, F., Campbell, M., & 
Chen, J. (2009). Prevalence of delirium with dexmedetomidine compared with morphine 
based therapy after cardiac surgery: A randomized controlled trial (dexmedetomidine 
compared to morphine-DEXCOM study). Anesthesiology, 111(5), 1075-1084.  
 
A) Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue? X   
2. Was the assignment of patients to treatments 
randomized? 
X   
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “blind” to treatment? 
X   
5. Were the groups similar at the start of the 
trial? 
X   
6. Aside from the experimental intervention, 
were the groups treated equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
299 cardiac surgical patients  
 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Reduced duration, but not incidence of 
POD in dexmedetomidine group versus 
the morphine group 
  
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your context? 
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and costs?
    
X   
Note. POD-postoperative delirium   
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        Appendix C 
Table C-5 
 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 5: Li, X., Yang, J., Nie, X. L., Zhang, Y., Li, X. Y., Li, L. H., Wang, D. X., & Ma, D. 
(2017). Impact of dexmedetomidine on the incidence of delirium in elderly patients after 
cardiac surgery: A randomized controlled trial. PLoS ONE, 12(2), 1-15. 
 
A) Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue? X   
2. Was the assignment of patients to treatments 
randomized? 
X   
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “blind” to treatment? 
X   
5. Were the groups similar at the start of the 
trial? 
X   
6. Aside from the experimental intervention, 
were the groups treated equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
 
285 cardiac surgical patients  
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Incidence of POD was not decreased in 
the dexmedetomidine group when 
compared with the control group 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your context? 
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and costs?
    
X   
Note. POD-postoperative delirium   
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      Appendix C 
Table C-6 
 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 6: Wanat, M., Fitousis, K., Boston, F., & Masud, F. (2014). Comparison of 
dexmedetomidine versus propofol for sedation in mechanically ventilated patients after 
cardiovascular surgery. Methodist DeBakey Cardiovascular Journal, 10(2), 111-117. 
 
A) Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue? X   
2. Was the assignment of patients to treatments 
randomized? 
  X 
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
X   
4. Were patients, health workers, and study 
personnel “blind” to treatment? 
  X 
5. Were the groups similar at the start of the 
trial? 
  X 
6. Aside from the experimental intervention, 
were the groups treated equally? 
 X  
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
352 cardiac surgical patients  
 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
No significant decrease in POD in 
dexmedetomidine group versus propofol 
group 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your context? 
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and costs?
    
X   
Note. POD-postoperative delirium   
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Cross Study Analysis  
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Author, 
Year 
Postoperative 
Sedative Protocol 
Outcome: 
Incidence of 
Delirium 
 
Outcome: Mean 
Length of 
Delirium (days) 
Outcome:  
Time to 
Extubation (hrs) 
 
Outcome: ICU 
LOS (hrs) 
Outcome: 
Hospital LOS 
(hrs) 
Study 1 
(Park et al., 
2014) 
Dexmedetomidine 
Loading dose: 0.5 
mcg/kg 
Maintenance dose: 
0.2-0.8 mcg/kg/hr 
 
Remifentanil 
Infusion: 1,000-
2,500 mcg/hr 
The overall 
prevalence of 
delirium during the 
initial postoperative 
period (first three 
days) was 16% (23 
of 142), with 8.96% 
(6 of 67) occurring 
in the 
dexmedetomidine 
group and 22.67% 
(17 of 75) in the 
remifentanil group. 
 
Decreased in the 
dexmedetomidine 
group when 
compared to the 
remifentanil group 
(3.76 ± 4.13).  
 
Increased in the 
dexmedetomidine 
group (22.72 ± 
26.36) when 
compared to the 
remifentanil 
group (18.60 ± 
19.74). 
 
Increased in the 
dexmedetomidine 
group (67.71 ± 
48.41) when 
compared to the 
remifentanil 
group (61.24 ± 
30.57).  
 
Increased in 
dexmedetomidine 
group (19.96 ± 
11.76) when 
compared to the 
remifentanil group 
(18.37 ± 8.45). 
 
Study 2 
(Djaiani et 
al., 2015) 
Dexmedetomidine 
Loading dose: 0.4 
mcg/kg 
Maintenance dose: 
0.2-0.7 mcg/kg/hr 
 
Propofol 
Infusion: 25-50 
mcg/kg/min 
The overall 
prevalence of 
delirium during the 
initial postoperative 
period (first five 
days) was 24.6% 
(45 of 183), with 
17.5% (16 of 91) 
occurring in the 
dexmedetomidine 
group and 31.5% 
(29 of 92) in the 
propofol group. 
 
 
Decreased in the 
dexmedetomidine 
group (2 days) 
when compared to 
the propofol group 
(3 days). 
 
 
Decreased in 
dexmedetomidine 
group (5.5 hrs) 
when compared 
to the propofol 
group (7.6 hrs).  
 
Decreased in 
dexmedetomidine 
group (67.8 hrs) 
when compared 
to the propofol 
group (76.5 hrs). 
 
Decreased in 
dexmedetomidine 
group (7.5 days) 
when compared to 
the propofol group 
(10 days). 
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Study 3  
(Maldonado 
et al., 2009) 
Dexmedetomidine 
Loading dose: 0.4 
mcg/kg 
Maintenance dose: 
0.2-0.7 mcg/kg/hr 
 
Propofol 
Infusion: 25-50 
mcg/kg/min 
 
Midazolam  
Infusion: 0.5-2 
mg/hr 
The overall 
prevalence of 
delirium during the 
initial postoperative 
period (first three 
days) was 34% (31 
of 90), with 3% (1 
of 30) occurring in 
the 
dexmedetomidine 
group, 50% (15 of 
30) occurring in the 
propofol group, and 
50% (15 of 30) 
occurring in the 
midazolam group. 
 
Decreased in the 
dexmedetomidine 
group (2 days) 
when compared 
with the propofol 
(3 days) and 
midazolam groups 
(5.4 days).  
 
Increased in the 
dexmedetomidine 
group (11.9 hrs) 
when compared 
with the propofol 
group (11.1 hrs) 
but decreased 
when compared 
with the 
midazolam group 
(12.7 hrs). 
 
Decreased in the 
dexmedetomidine 
group (1.7 days) 
when compared 
with the propofol 
and midazolam 
groups (3.0 days) 
respectively. 
 
 
Decreased in the 
dexmedetomidine 
group (7.1 days) 
when compared 
with the propfol 
(8.2 days) and 
midazolam groups 
(8.9 days) 
respectively.    
 
Study 4  
(Shehabi et 
al., 2009) 
Dexmedetomidine  
No loading dose 
Maintenance dose: 
0.1-0.7 mcg/kg/hr 
 
Morphine  
Infusion: 10-70 
mcg/kg/hr 
The overall 
incidence of 
delirium during the 
initial postoperative 
period (first five 
days) was 11.7% 
(35 of 299), with 
8.6% (13 of 152) 
occurring in the 
dexmedetomidine 
group and 15% (22 
of 147) in the 
morphine group. 
 
 
 
Decreased in the 
dexmedetomidine 
group (2 days) 
when compared 
with the morphine 
group (5 days).  
 
Decreased in 
dexmedetomidine 
group (14 hrs) 
when compared 
to the morphine 
group (15 hrs).  
 
Equal in both the 
dexmedetomidine 
and morphine 
groups (45 hrs). 
 
Equal in both the 
dexmedetomidine 
and morphine 
groups (8 days).  
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Study 5  
(Li et al., 
2017) 
Dexmedetomidine  
In OR: 0.6 mcg/kg 
(1st 10 mins) 
followed by 0.4 
mcg/kg/hr intra-op 
Maintenance dose: 
0.1 mcg/kg/hr until 
end of mechanical 
ventilation.  
 
Normal saline  
No administration 
protocol followed 
The overall 
prevalence of 
delirium during the 
initial postoperative 
period (first five 
days) was 6.67% 
(19 of 285), with 
4.9% (7 of 142) 
occurring in the 
dexmedetomidine 
group and 7.7% (11 
of 143) in the 
control group. 
 
Equal in both the 
dexmedetomidine 
and control groups 
(2 days). 
 
Equal in both the 
dexmedetomidine 
and morphine 
groups (15 hrs). 
 
Slightly 
decreased in the 
dexmedetomidine 
group (45 hrs) 
compared to the 
control groups 
(46 hrs).  
 
Equal in both the 
dexmedetomidine 
and control groups 
(9 days) 
 
Study 6  
(Wanat et 
al., 2014) 
 
Dexmedetomidine  
Infusion: 0.4-0.6 
mcg/kg/hr. 
 
Propofol  
Infusion: 30-50 
mcg/kg/hr. 
 
The overall 
prevalence of 
delirium during the 
initial postoperative 
period was 7.67% 
(27 of 352), with 
9.09% (3 of 33) 
occurring in the 
dexmedetomidine 
group and 7.53% 
(24 of 319) in the 
propofol group. 
 
Mean length of 
delirium was not a 
variable measured 
in this study, 
conversely, the 
requirement of an 
additional sedative 
agent was 
reviewed and 
revealed that the 
incidence was 
decreased in the 
dexmedetomidine 
group (8) when 
compared with the 
propofol group 
(86).  
 
Decreased in the 
dexmedetomidine 
group (7.37 ± 
4.30) when 
compared with 
the propofol 
group (12.88 ± 
15.42). 
 
Decreased in the 
dexmedetomidine 
group (2.55 ± 
2.95) when 
compared with 
the propofol 
group (3.99 ± 
4.78). 
 
Decreased in the 
dexmedetomidine 
group (9.79 ± 
6.77) when 
compared with the 
propofol group 
(12.42 ± 7.44). 
 
Note. All data tables discussed in the cross-study analysis are included under Appendices A, B, and C.  
 
